WO2006080477A1 - Norvaline derivative and method for preparation thereof - Google Patents
Norvaline derivative and method for preparation thereof Download PDFInfo
- Publication number
- WO2006080477A1 WO2006080477A1 PCT/JP2006/301394 JP2006301394W WO2006080477A1 WO 2006080477 A1 WO2006080477 A1 WO 2006080477A1 JP 2006301394 W JP2006301394 W JP 2006301394W WO 2006080477 A1 WO2006080477 A1 WO 2006080477A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- optionally substituted
- compound
- group
- lower alkyl
- glyt2
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 30
- BADANQBWOZJJJH-UHFFFAOYSA-N 2-amino-2-hydroxy-3-oxopentanoic acid Chemical compound CCC(=O)C(N)(O)C(O)=O BADANQBWOZJJJH-UHFFFAOYSA-N 0.000 title claims abstract description 7
- 238000002360 preparation method Methods 0.000 title description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 180
- 150000003839 salts Chemical class 0.000 claims abstract description 71
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 40
- 125000002947 alkylene group Chemical group 0.000 claims abstract description 18
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 14
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 11
- 125000003107 substituted aryl group Chemical group 0.000 claims abstract description 6
- -1 1-piperidyl Chemical group 0.000 claims description 27
- 238000011282 treatment Methods 0.000 claims description 16
- 230000005764 inhibitory process Effects 0.000 claims description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
- 208000002193 Pain Diseases 0.000 claims description 13
- 125000005843 halogen group Chemical group 0.000 claims description 13
- 230000036407 pain Effects 0.000 claims description 13
- 125000003277 amino group Chemical group 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 238000011321 prophylaxis Methods 0.000 claims description 11
- 125000001424 substituent group Chemical group 0.000 claims description 11
- 208000004296 neuralgia Diseases 0.000 claims description 9
- 208000021722 neuropathic pain Diseases 0.000 claims description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- 206010065390 Inflammatory pain Diseases 0.000 claims description 6
- 208000008238 Muscle Spasticity Diseases 0.000 claims description 6
- 208000009205 Tinnitus Diseases 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 206010015037 epilepsy Diseases 0.000 claims description 6
- 231100000886 tinnitus Toxicity 0.000 claims description 6
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 5
- 125000001624 naphthyl group Chemical group 0.000 claims description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 5
- 208000014001 urinary system disease Diseases 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 4
- 125000004414 alkyl thio group Chemical group 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 3
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 102100028886 Sodium- and chloride-dependent glycine transporter 2 Human genes 0.000 claims 6
- 101710083167 Sodium- and chloride-dependent glycine transporter 2 Proteins 0.000 claims 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 239000004615 ingredient Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 24
- 230000000694 effects Effects 0.000 abstract description 14
- 108010063380 Glycine Plasma Membrane Transport Proteins Proteins 0.000 abstract description 13
- 102000010726 Glycine Plasma Membrane Transport Proteins Human genes 0.000 abstract description 13
- 239000001257 hydrogen Substances 0.000 abstract description 9
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract description 7
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 abstract 1
- 125000001931 aliphatic group Chemical group 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 64
- PCBOWMZAEDDKNH-HOTGVXAUSA-N [4-(trifluoromethoxy)phenyl]methyl (3as,6as)-2-(3-fluoro-4-sulfamoylbenzoyl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole-5-carboxylate Chemical compound C1=C(F)C(S(=O)(=O)N)=CC=C1C(=O)N1C[C@H]2CN(C(=O)OCC=3C=CC(OC(F)(F)F)=CC=3)C[C@@H]2C1 PCBOWMZAEDDKNH-HOTGVXAUSA-N 0.000 description 61
- 239000002904 solvent Substances 0.000 description 59
- 239000000243 solution Substances 0.000 description 57
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 52
- 230000002829 reductive effect Effects 0.000 description 48
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 42
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 36
- 239000011541 reaction mixture Substances 0.000 description 35
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 30
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 29
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- 238000010898 silica gel chromatography Methods 0.000 description 27
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 25
- 239000012044 organic layer Substances 0.000 description 25
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 24
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 24
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 16
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 16
- 239000004471 Glycine Substances 0.000 description 15
- 238000001914 filtration Methods 0.000 description 14
- 125000004432 carbon atom Chemical group C* 0.000 description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 125000006239 protecting group Chemical group 0.000 description 10
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 8
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- 210000000278 spinal cord Anatomy 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 229940086542 triethylamine Drugs 0.000 description 6
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 5
- 102000011714 Glycine Receptors Human genes 0.000 description 5
- 108010076533 Glycine Receptors Proteins 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 4
- MWAYRGBWOVHDDZ-UHFFFAOYSA-N Ethyl vanillate Chemical compound CCOC(=O)C1=CC=C(O)C(OC)=C1 MWAYRGBWOVHDDZ-UHFFFAOYSA-N 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 229910052783 alkali metal Inorganic materials 0.000 description 4
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 4
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 239000002858 neurotransmitter agent Substances 0.000 description 4
- 229910052763 palladium Inorganic materials 0.000 description 4
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 108010078791 Carrier Proteins Proteins 0.000 description 3
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- 208000000114 Pain Threshold Diseases 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 210000000133 brain stem Anatomy 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 3
- 230000000575 glycinergic effect Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000007913 intrathecal administration Methods 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000037040 pain threshold Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 3
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- MNDIARAMWBIKFW-UHFFFAOYSA-N 1-bromohexane Chemical compound CCCCCCBr MNDIARAMWBIKFW-UHFFFAOYSA-N 0.000 description 2
- HBQUXMZZODHFMJ-UHFFFAOYSA-N 4-hexoxybenzoic acid Chemical compound CCCCCCOC1=CC=C(C(O)=O)C=C1 HBQUXMZZODHFMJ-UHFFFAOYSA-N 0.000 description 2
- OMNHTTWQSSUZHO-UHFFFAOYSA-N 4-hydroxy-3,5-dimethylbenzoic acid Chemical compound CC1=CC(C(O)=O)=CC(C)=C1O OMNHTTWQSSUZHO-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- 208000004454 Hyperalgesia Diseases 0.000 description 2
- 208000035154 Hyperesthesia Diseases 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000010306 acid treatment Methods 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 150000003862 amino acid derivatives Chemical class 0.000 description 2
- 230000003444 anaesthetic effect Effects 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- BGTOWKSIORTVQH-UHFFFAOYSA-N cyclopentanone Chemical compound O=C1CCCC1 BGTOWKSIORTVQH-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- KBPUBCVJHFXPOC-UHFFFAOYSA-N ethyl 3,4-dihydroxybenzoate Chemical compound CCOC(=O)C1=CC=C(O)C(O)=C1 KBPUBCVJHFXPOC-UHFFFAOYSA-N 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- GRWIABMEEKERFV-UHFFFAOYSA-N methanol;oxolane Chemical compound OC.C1CCOC1 GRWIABMEEKERFV-UHFFFAOYSA-N 0.000 description 2
- UKZOPQRTQJERQC-UHFFFAOYSA-N methyl 6-hydroxynaphthalene-2-carboxylate Chemical compound C1=C(O)C=CC2=CC(C(=O)OC)=CC=C21 UKZOPQRTQJERQC-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- 239000003158 myorelaxant agent Substances 0.000 description 2
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- QMGVPVSNSZLJIA-FVWCLLPLSA-N strychnine Chemical compound O([C@H]1CC(N([C@H]2[C@H]1[C@H]1C3)C=4C5=CC=CC=4)=O)CC=C1CN1[C@@H]3[C@]25CC1 QMGVPVSNSZLJIA-FVWCLLPLSA-N 0.000 description 2
- 230000000946 synaptic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- VUXIWECKDVXDBG-LURJTMIESA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanethioic s-acid Chemical compound CC[C@@H](C(S)=O)NC(=O)OC(C)(C)C VUXIWECKDVXDBG-LURJTMIESA-N 0.000 description 1
- PNFVIPIQXAIUAY-LURJTMIESA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid Chemical compound CC[C@@H](C(O)=O)NC(=O)OC(C)(C)C PNFVIPIQXAIUAY-LURJTMIESA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- CYSGHNMQYZDMIA-UHFFFAOYSA-N 1,3-Dimethyl-2-imidazolidinon Chemical compound CN1CCN(C)C1=O CYSGHNMQYZDMIA-UHFFFAOYSA-N 0.000 description 1
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- YUBDLZGUSSWQSS-UHFFFAOYSA-N 1-benzylpiperidin-4-amine Chemical compound C1CC(N)CCN1CC1=CC=CC=C1 YUBDLZGUSSWQSS-UHFFFAOYSA-N 0.000 description 1
- ORLCYMQZIPSODD-UHFFFAOYSA-N 1-chloro-2-[chloro(2,2,2-trichloroethoxy)phosphoryl]oxybenzene Chemical compound ClC1=CC=CC=C1OP(Cl)(=O)OCC(Cl)(Cl)Cl ORLCYMQZIPSODD-UHFFFAOYSA-N 0.000 description 1
- BMVXCPBXGZKUPN-UHFFFAOYSA-N 1-hexanamine Chemical compound CCCCCCN BMVXCPBXGZKUPN-UHFFFAOYSA-N 0.000 description 1
- KMRWHESBJZFGFH-UHFFFAOYSA-N 1-methylpiperazin-2-one;hydrochloride Chemical compound Cl.CN1CCNCC1=O KMRWHESBJZFGFH-UHFFFAOYSA-N 0.000 description 1
- LJCZNYWLQZZIOS-UHFFFAOYSA-N 2,2,2-trichlorethoxycarbonyl chloride Chemical compound ClC(=O)OCC(Cl)(Cl)Cl LJCZNYWLQZZIOS-UHFFFAOYSA-N 0.000 description 1
- BGJWIQJENOLUFO-NRFANRHFSA-N 2,2,2-trichloroethyl 4-[[(2s)-2-[(3,5-dimethoxy-4-phenylmethoxybenzoyl)amino]-3-methoxypropanoyl]amino]piperidine-1-carboxylate Chemical compound N([C@@H](COC)C(=O)NC1CCN(CC1)C(=O)OCC(Cl)(Cl)Cl)C(=O)C(C=C1OC)=CC(OC)=C1OCC1=CC=CC=C1 BGJWIQJENOLUFO-NRFANRHFSA-N 0.000 description 1
- SRNASCIHZANCBB-FVGYRXGTSA-N 2,2,2-trichloroethyl 4-[[(2s)-2-amino-3-methoxypropanoyl]amino]piperidine-1-carboxylate;hydrochloride Chemical compound Cl.COC[C@H](N)C(=O)NC1CCN(C(=O)OCC(Cl)(Cl)Cl)CC1 SRNASCIHZANCBB-FVGYRXGTSA-N 0.000 description 1
- OZGSEIVTQLXWRO-UHFFFAOYSA-N 2,4,6-trichlorobenzoyl chloride Chemical compound ClC(=O)C1=C(Cl)C=C(Cl)C=C1Cl OZGSEIVTQLXWRO-UHFFFAOYSA-N 0.000 description 1
- PNHGJPJOMCXSKN-UHFFFAOYSA-N 2-(1-methylpyrrolidin-2-yl)ethanamine Chemical compound CN1CCCC1CCN PNHGJPJOMCXSKN-UHFFFAOYSA-N 0.000 description 1
- VZOQYVHEWHJIBG-UHFFFAOYSA-N 2-(aminomethyl)benzamide Chemical class NCC1=CC=CC=C1C(N)=O VZOQYVHEWHJIBG-UHFFFAOYSA-N 0.000 description 1
- RIDGSEGTBIWFTK-UHFFFAOYSA-N 2-(dimethylamino)-2-methylpropanenitrile Chemical compound CN(C)C(C)(C)C#N RIDGSEGTBIWFTK-UHFFFAOYSA-N 0.000 description 1
- JCCMABJHLXQFRX-UHFFFAOYSA-N 2-(hexylamino)benzoic acid Chemical compound CCCCCCNC1=CC=CC=C1C(O)=O JCCMABJHLXQFRX-UHFFFAOYSA-N 0.000 description 1
- JPDYKGXRRPYJAI-UHFFFAOYSA-N 2-[1-(dimethylamino)cyclopentyl]acetonitrile Chemical compound N#CCC1(N(C)C)CCCC1 JPDYKGXRRPYJAI-UHFFFAOYSA-N 0.000 description 1
- GWXSDLJKQUFJFC-UHFFFAOYSA-N 2-[1-(methylamino)cyclopentyl]acetonitrile Chemical compound N#CCC1(NC)CCCC1 GWXSDLJKQUFJFC-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- DNAYRSBMBDMJNU-UHFFFAOYSA-N 2-cyclopentylideneacetonitrile Chemical compound N#CC=C1CCCC1 DNAYRSBMBDMJNU-UHFFFAOYSA-N 0.000 description 1
- KWMBADTWRIGGGG-UHFFFAOYSA-N 2-diethoxyphosphorylacetonitrile Chemical compound CCOP(=O)(CC#N)OCC KWMBADTWRIGGGG-UHFFFAOYSA-N 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- PKZCRWFNSBIBEW-UHFFFAOYSA-N 2-n,2-n,2-trimethylpropane-1,2-diamine Chemical compound CN(C)C(C)(C)CN PKZCRWFNSBIBEW-UHFFFAOYSA-N 0.000 description 1
- UOBYKYZJUGYBDK-UHFFFAOYSA-N 2-naphthoic acid Chemical compound C1=CC=CC2=CC(C(=O)O)=CC=C21 UOBYKYZJUGYBDK-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- OVCCGNWMGBKDIZ-UHFFFAOYSA-N 3,5-dimethoxy-4-phenylmethoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=CC(OC)=C1OCC1=CC=CC=C1 OVCCGNWMGBKDIZ-UHFFFAOYSA-N 0.000 description 1
- RDBSDXSYXWYCKA-UHFFFAOYSA-N 3-formamido-4-hexoxybenzoic acid Chemical compound CCCCCCOC1=CC=C(C(O)=O)C=C1NC=O RDBSDXSYXWYCKA-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- XWCWFMQMZZPALR-UHFFFAOYSA-N 4-(4-phenylbutoxy)benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1OCCCCC1=CC=CC=C1 XWCWFMQMZZPALR-UHFFFAOYSA-N 0.000 description 1
- LBUNNMJLXWQQBY-UHFFFAOYSA-N 4-fluorophenylboronic acid Chemical compound OB(O)C1=CC=C(F)C=C1 LBUNNMJLXWQQBY-UHFFFAOYSA-N 0.000 description 1
- RSKCZCPQRVUGHL-UHFFFAOYSA-N 4-hexoxy-3,5-dimethylbenzoic acid Chemical compound CCCCCCOC1=C(C)C=C(C(O)=O)C=C1C RSKCZCPQRVUGHL-UHFFFAOYSA-N 0.000 description 1
- SKORYIRZDOGKDE-UHFFFAOYSA-N 4-hexoxy-3-(methoxymethoxy)benzoic acid Chemical compound CCCCCCOC1=CC=C(C(O)=O)C=C1OCOC SKORYIRZDOGKDE-UHFFFAOYSA-N 0.000 description 1
- YLAUGHKKFJXKMP-UHFFFAOYSA-N 4-hexoxy-3-methoxy-5-methylbenzoic acid Chemical compound CCCCCCOC1=C(C)C=C(C(O)=O)C=C1OC YLAUGHKKFJXKMP-UHFFFAOYSA-N 0.000 description 1
- LDZLXQFDGRCELX-UHFFFAOYSA-N 4-phenylbutan-1-ol Chemical compound OCCCCC1=CC=CC=C1 LDZLXQFDGRCELX-UHFFFAOYSA-N 0.000 description 1
- BTBFNOYVZDSVPX-UHFFFAOYSA-N 4-phenylbutyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCCCCC1=CC=CC=C1 BTBFNOYVZDSVPX-UHFFFAOYSA-N 0.000 description 1
- SPXMGBQISWMKGW-UHFFFAOYSA-N 5-nitro-6-piperidin-1-ylnaphthalene-2-carboxylic acid Chemical compound C1=CC2=CC(C(=O)O)=CC=C2C([N+]([O-])=O)=C1N1CCCCC1 SPXMGBQISWMKGW-UHFFFAOYSA-N 0.000 description 1
- ZHUWZHDMISEJGG-UHFFFAOYSA-N 6-(4-fluorophenoxy)naphthalene-2-carboxylic acid Chemical compound C1=CC2=CC(C(=O)O)=CC=C2C=C1OC1=CC=C(F)C=C1 ZHUWZHDMISEJGG-UHFFFAOYSA-N 0.000 description 1
- BNMIGHLFXDYZGD-UHFFFAOYSA-N 6-phenylnaphthalene-2-carboxylic acid Chemical compound C1=CC2=CC(C(=O)O)=CC=C2C=C1C1=CC=CC=C1 BNMIGHLFXDYZGD-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- XJUZRXYOEPSWMB-UHFFFAOYSA-N Chloromethyl methyl ether Chemical compound COCCl XJUZRXYOEPSWMB-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101000631937 Homo sapiens Sodium- and chloride-dependent glycine transporter 2 Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 241001279009 Strychnos toxifera Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000005236 alkanoylamino group Chemical group 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 1
- 150000003936 benzamides Chemical class 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- AOGYCOYQMAVAFD-UHFFFAOYSA-N chlorocarbonic acid Chemical class OC(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-N 0.000 description 1
- OQNGCCWBHLEQFN-UHFFFAOYSA-N chloroform;hexane Chemical compound ClC(Cl)Cl.CCCCCC OQNGCCWBHLEQFN-UHFFFAOYSA-N 0.000 description 1
- 229940061627 chloromethyl methyl ether Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- VLNZUSMTOFYNPS-UHFFFAOYSA-N diethylphosphorylformonitrile Chemical compound CCP(=O)(CC)C#N VLNZUSMTOFYNPS-UHFFFAOYSA-N 0.000 description 1
- 229940113088 dimethylacetamide Drugs 0.000 description 1
- XHFGWHUWQXTGAT-UHFFFAOYSA-N dimethylamine hydrochloride Natural products CNC(C)C XHFGWHUWQXTGAT-UHFFFAOYSA-N 0.000 description 1
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000000119 electrospray ionisation mass spectrum Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- LSCUOFWTNXUEKI-UHFFFAOYSA-N ethyl 3-amino-4-hexoxybenzoate Chemical compound CCCCCCOC1=CC=C(C(=O)OCC)C=C1N LSCUOFWTNXUEKI-UHFFFAOYSA-N 0.000 description 1
- PAPHTHVASNPOHW-UHFFFAOYSA-N ethyl 3-formyl-4-hydroxy-5-methoxybenzoate Chemical compound CCOC(=O)C1=CC(OC)=C(O)C(C=O)=C1 PAPHTHVASNPOHW-UHFFFAOYSA-N 0.000 description 1
- NJSOFDOTSSUMPB-UHFFFAOYSA-N ethyl 4-hexoxy-3-(methoxymethoxy)benzoate Chemical compound CCCCCCOC1=CC=C(C(=O)OCC)C=C1OCOC NJSOFDOTSSUMPB-UHFFFAOYSA-N 0.000 description 1
- KGHOUWPJICSBOS-UHFFFAOYSA-N ethyl 4-hexoxy-3-hydroxybenzoate Chemical compound CCCCCCOC1=CC=C(C(=O)OCC)C=C1O KGHOUWPJICSBOS-UHFFFAOYSA-N 0.000 description 1
- UQKSMROIAYMCHW-UHFFFAOYSA-N ethyl 4-hexoxy-3-methoxybenzoate Chemical compound CCCCCCOC1=CC=C(C(=O)OCC)C=C1OC UQKSMROIAYMCHW-UHFFFAOYSA-N 0.000 description 1
- QAZQLZXBKAHFFM-UHFFFAOYSA-N ethyl 4-hydroxy-3-methoxy-5-methylbenzoate Chemical compound CCOC(=O)C1=CC(C)=C(O)C(OC)=C1 QAZQLZXBKAHFFM-UHFFFAOYSA-N 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 235000010299 hexamethylene tetramine Nutrition 0.000 description 1
- 239000004312 hexamethylene tetramine Substances 0.000 description 1
- RZBFCGQOULTXBE-UHFFFAOYSA-N hexyl 4-hexoxy-3,5-dimethylbenzoate Chemical compound CCCCCCOC(=O)C1=CC(C)=C(OCCCCCC)C(C)=C1 RZBFCGQOULTXBE-UHFFFAOYSA-N 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- CEAJFNBWKBTRQE-UHFFFAOYSA-N methanamine;methanol Chemical compound NC.OC CEAJFNBWKBTRQE-UHFFFAOYSA-N 0.000 description 1
- QZBZTVGOZTUSBR-UHFFFAOYSA-N methyl 2-(hexylamino)benzoate Chemical compound CCCCCCNC1=CC=CC=C1C(=O)OC QZBZTVGOZTUSBR-UHFFFAOYSA-N 0.000 description 1
- IODNYRVZHKRFIW-UHFFFAOYSA-N methyl 2-aminopentanoate;hydrochloride Chemical compound Cl.CCCC(N)C(=O)OC IODNYRVZHKRFIW-UHFFFAOYSA-N 0.000 description 1
- DANIQBBSCFSRRQ-UHFFFAOYSA-N methyl 3-formamido-4-hexoxybenzoate Chemical compound CCCCCCOC1=CC=C(C(=O)OC)C=C1NC=O DANIQBBSCFSRRQ-UHFFFAOYSA-N 0.000 description 1
- MSEBQGULDWDIRW-UHFFFAOYSA-N methyl 4-fluorobenzoate Chemical compound COC(=O)C1=CC=C(F)C=C1 MSEBQGULDWDIRW-UHFFFAOYSA-N 0.000 description 1
- QHLHTGXVXANIAM-UHFFFAOYSA-N methyl 4-hexoxy-3-nitrobenzoate Chemical compound CCCCCCOC1=CC=C(C(=O)OC)C=C1[N+]([O-])=O QHLHTGXVXANIAM-UHFFFAOYSA-N 0.000 description 1
- GNCWCTBHZCBXGL-UHFFFAOYSA-N methyl 4-hydroxy-3-nitrobenzoate Chemical compound COC(=O)C1=CC=C(O)C([N+]([O-])=O)=C1 GNCWCTBHZCBXGL-UHFFFAOYSA-N 0.000 description 1
- QUMSAJWZNVRENY-UHFFFAOYSA-N methyl 5-nitro-6-(trifluoromethylsulfonyloxy)naphthalene-2-carboxylate Chemical compound [O-][N+](=O)C1=C(OS(=O)(=O)C(F)(F)F)C=CC2=CC(C(=O)OC)=CC=C21 QUMSAJWZNVRENY-UHFFFAOYSA-N 0.000 description 1
- JCOWPRQGWPGTJW-UHFFFAOYSA-N methyl 5-nitro-6-phenylnaphthalene-2-carboxylate Chemical compound C1=CC2=CC(C(=O)OC)=CC=C2C([N+]([O-])=O)=C1C1=CC=CC=C1 JCOWPRQGWPGTJW-UHFFFAOYSA-N 0.000 description 1
- YQYPOCHMRJGSOS-UHFFFAOYSA-N methyl 5-nitro-6-piperidin-1-ylnaphthalene-2-carboxylate Chemical compound C1=CC2=CC(C(=O)OC)=CC=C2C([N+]([O-])=O)=C1N1CCCCC1 YQYPOCHMRJGSOS-UHFFFAOYSA-N 0.000 description 1
- SMQZWPNTSFLEQO-UHFFFAOYSA-N methyl 6-(4-fluorophenoxy)naphthalene-2-carboxylate Chemical compound C1=CC2=CC(C(=O)OC)=CC=C2C=C1OC1=CC=C(F)C=C1 SMQZWPNTSFLEQO-UHFFFAOYSA-N 0.000 description 1
- JEUBRLPXJZOGPX-UHFFFAOYSA-N methyl 6-bromonaphthalene-2-carboxylate Chemical compound C1=C(Br)C=CC2=CC(C(=O)OC)=CC=C21 JEUBRLPXJZOGPX-UHFFFAOYSA-N 0.000 description 1
- AVCYAFWDASFXER-UHFFFAOYSA-N methyl 6-hydroxy-5-nitronaphthalene-2-carboxylate Chemical compound [O-][N+](=O)C1=C(O)C=CC2=CC(C(=O)OC)=CC=C21 AVCYAFWDASFXER-UHFFFAOYSA-N 0.000 description 1
- ZVPJBLRISSXOBJ-UHFFFAOYSA-N methyl 6-phenylnaphthalene-2-carboxylate Chemical compound C1=CC2=CC(C(=O)OC)=CC=C2C=C1C1=CC=CC=C1 ZVPJBLRISSXOBJ-UHFFFAOYSA-N 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 description 1
- MWDCCRWZGLSKGS-UHFFFAOYSA-N n-methylmethanamine;dihydrochloride Chemical compound Cl.Cl.CNC MWDCCRWZGLSKGS-UHFFFAOYSA-N 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 210000001032 spinal nerve Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005453 strychnine Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Definitions
- the present invention relates to a novel norvaline derivative, which exhibits an excellent inhibitory activity on glycine transporter type 2: GlyT2 and is useful as a medicament, and a method for preparation the same and a use thereof.
- Glycine is one of inhibitory neurotransmitters. Glycine shows an inhibitory activity on sensory nerves through strychnine-sensitive glycine receptors (ssGlyRs) in the spinal cord and the brain stem of a vertebrate.
- ssGlyRs strychnine-sensitive glycine receptors
- a pain threshold is elevated by intrathecal administration of glycine, while it is lowered by intrathecal administration of strychnine having a glycine receptor antagonistic activity.
- Those results suggest that a pain threshold may be kept at a certain level or higher by stimulation of strychnine-sensitive glycine receptors by glycine in the spinal cord.
- glycine-specific transporters there have been known ' two classes such as glycine transporter type 1: GIyTl (including subtypes:
- GlyT2 (including subtypes: GlyT2a, GlyT2b), and genes thereof were cloned one after another in the 1990s [Guastella et al., Proc. Natl. Acad. Sci. USA 5 1992, 89, 7189; Liu et al., FEBS Lett., 1992, 305, 110; Smith et al., Neuron, 1992, 8, 927; Borosky et al., Neuron, 1993, 10, 851].
- GIyT 1 is widely distributed in the central nervous system: CNS, and existing mainly in glia cells and it has been considered that GIyTl has a role to maintain a low concentration of glycine in an extracellular fluid.
- GlyT2 exists locally in the brain stem and the spinal cord. GlyT2 takes a role in the reuptake system of glycine acting as a neurotransmitter in the brain stem and the spinal cord, and removes glycine from a synaptic space and inactivates glycinergic neuro-activity. Further, GlyT2 has the same distribution pattern as strychnine-sensitive glycine receptor: ssGlyR, and closely relates to the inhibitory system through strychnine-sensitive glycine receptors.
- GlyT2 inhibitor shows an effect of improving hyperalgesia by increasing a pain threshold in neuropathic pain models [Houghton et al., 31 st Society of Neuroscience Meeting Abstracts 2001, 27 (Abs 283.1)] .
- GlyT2 inhibitors are considered as being useful for treatment of urological disorders [WO 2005/94808 (Bayer Healthcare)]. Consequently, GlyT2 inhibitors have been expected to be developed as an excellent medicament. Particularly, neuropathic pain syndromes are difficult to be cured, and available medicaments for neuropathic pain such as ⁇ -Opioid, etc. often show side effects to the central nervous system, and thus, it has strongly been demanded to develop an excellent medicament therefor.
- amino acid derivatives having GlyT2 inhibiting activity are disclosed in the literature of Isaac et al. (Isaac et al, Bioorg. Med. Chem. Lett. 2001, 11, 1371-1373) (NPS); benzamide derivatives such as N-[(l-dimethylaminocycloalkyl)methyl]benzamide derivatives, 2- (aminomethyl) benzamide derivatives, etc. are disclosed in WO 2003/ 10132 (Akzo Nobel), the literature of Caulfield et al. (Caulfield et al., Journal of Medicinal Chemistry, 2001, 44, 2679-2682) and the literature of Ho et al. (Ho et al., Bioorganic & Medicinal Chemistry Letters, 2004, 14, 545-548).
- ⁇ , ⁇ and ⁇ amino acid derivatives are disclosed in the literatures of Wolin et al. (Wolin et al., Bioorganic 8B Medicinal Chemistry, 2004, 12:4477-4492; Wolin et al., Bioorganic & Medicinal Chemistry, 2004, 12:4493-4509) and WO 2005/044810 (Janssen Pharmaceutica).
- the present invention provides a novel compound having an excellent inhibitory activity on glycine transporter type 2: GlyT2, a method for preparation thereof, and a use of the same and a pharmaceutical composition containing said compound etc.
- the present inventors have intensively studied and have found a norvaline derivative having an excellent inhibitory activity on glycine transporter type 2: GlyT2 to accomplish the present invention.
- the present invention relates to a norvaline derivative of the formula [I]:
- X is -CH2-, -O-, -S- or a single bond
- Ar is an optionally substituted aryl or an optionally substituted lower cycloalkyl; n is an integer of 0 to 2;
- R 1 and R 2 are the following (i), (ii) or (iii):
- each is independently a hydrogen atom or a lower alkyl;
- R 1 and R 2 are combined together to form a lower alkylene; or
- R 1 is a hydrogen atom or a lower alkyl and R 2 is combined
- R 3 and R 4 are the following (i), (ii) or (iii):
- each is independently a hydrogen atom or a lower alkyl;
- R 3 and R 4 are combined together to form a lower alkylene; or
- R 3 is a hydrogen atom or a lower alkyl and R 4 is combined together with R 2 or R 6 to form a lower alkylene, when R is R 6 ;
- R 5 and R 6 are the following (i), (ii) or (iii):
- each is independently a lower alkyl optionally substituted with hydroxyl group(s), or a hydrogen atom;
- R 5 and R 5 are combined together with the adjacent nitrogen atom to form an optionally substituted nitrogen-containing aliphatic 5- to 6- membered heterocyclic group;
- R 5 is a lower alkyl optionally substituted with hydroxyl group(s), or a hydrogen atom, and R 6 is combined together with R 2 or R 4 to form a lower alkylene;
- R 7 is a lower alkyl; provided that when R 5 and R 6 are combined together with the adjacent nitrogen atom to form a morpholine ring, then Ar has at least one substituent other than halogen atom, methoxy or phenyl; and when R is -OR 7 and X is a single bond, then Ar is an optionally substituted phenyl, an optionally substituted naphthyl or an optionally substituted lower cycloalkyl], or a pharmaceutically acceptable salt thereof.
- the present invention relates to a method for preparation of the above compound [I] or a pharmaceutically acceptable salt thereof.
- the present invention relates to a pharmaceutical composition containing the above compound [I] or a pharmaceutically acceptable salt thereof as an active ingredient.
- the present invention relates to a method for treatment or prophylaxis of a disease or condition, which comprises administering an effective amount of the above compound [I] or a pharmaceutically acceptable salt thereof to a patient. Still further, the present invention relates to a use of the above compound [I] or a pharmaceutically acceptable salt thereof for manufacture of a medicament.
- the present invention relates to a use of the above compound [I] or a pharmaceutically acceptable salt thereof for the inhibition of a transporting activity of glycine transporter type 2 (GlyT2) .
- the desired compound [I] of the present invention or a pharmaceutically acceptable salt thereof exhibits an excellent inhibitory activity on glycine transporter type 2: GlyT2.
- the pharmaceutical composition containing the desired compound of the present invention is useful as an active ingredient in a medicament for treatment or prophylaxis of a disease or condition (such as pain) which may be expected to be improved by inhibition of glycine transporter type 2: GlyT2.
- the desired compound [I] of the present invention may have optical isomers, and the present invention includes any of these isomers and also a mixture thereof.
- the lower alkyl group, the lower alkylthio group, the lower alkylsulfonyl group, the lower alkoxy group, and the lower alkylamino group include a straight chain or branched chain groups having 1-6 carbon atoms (Ci- ⁇ ), particularly ones having
- the lower alkanoyl group and the lower alkanoylamino group include ones having 2-7 carbon atoms (C2-7), particularly ones having 2-
- the lower alkanoyl group includes either one of a lower alkyl-
- the lower cycloalkyl group and the lower cycloalkenyl group include ones having 3-8 carbon atoms (C3-8), particularly ones having 3- 6 carbon atoms (C3-6) .
- the lower alkylene group includes a straight chain or branched chain groups having 1-6 carbon atoms (Ci- ⁇ ), particularly ones having 1-4 carbon atoms (Ci-4).
- the lower alkenyl group and the lower alkenylene group include ones having 2-7 carbon atoms (C2-7), particularly ones having 2-5 carbon atoms (C2-5).
- halogen atom includes, for example, a fluorine atom, a chlorine atom, a bromine atom or an iodine atom.
- the optionally substituted amino group includes, for example, unsubstituted amino group and mono- or di-substituted non-cyclic amino group, and further includes cyclic amino group (e.g., 1- pyrrolidinyl, 1-piperidyl, 1-piperazinyl, morpholin-4-yl, etc.).
- cyclic amino group e.g., 1- pyrrolidinyl, 1-piperidyl, 1-piperazinyl, morpholin-4-yl, etc.
- aryl 15 moiety of the "optionally substituted aryl" represented by Ar includes a monocyclic or a bicyclic aryl, including monocyclic or bicyclic aromatic hydrocarbon group, and also including monocyclic or bicyclic aromatic heterocyclic group (heteroaryl).
- Said aryl specifically includes, for example, phenyl and naphthyl etc.
- the lower cycloalkyl moiety of the "optionally substituted lower cycloalkyl" represented by Ar includes ones having 3-8 carbon atoms (C3-8), more preferably ones having 3-6 carbon atoms (C3-6). Said lower cycloalkyl specifically includes, for example, cyclohexyl etc.
- optionally substituted lower cycloalkyl represented by Ar may be one or more (preferably 1 to 3), and includes, for example, halogen atom (such as Cl, F, etc.); nitro group; cyano group; hydroxyl group; " optionally substituted amino group [e.g., amino group optionally substituted with 1 or 2 substituent(s) selected from lower alkyl and
- the lower alkyl represented by R 1 , R 2 , R 3 or R 4 may be methyl, etc.
- the lower alkylene formed by combining R 1 and R 2 or R 3 and R 4 may be, for example, n-propane-l,3-diyl, n-butane-l,4-diyl, etc.
- the lower alkylene formed by combining R 2 and R 4 , R 2 and R 6 , or R 4 and R 6 may be, for example, n-propane-l,3-diyl, n-butane-l,4-diyl, etc.
- the lower alkyl moiety of the "optionally substituted lower alkyl” represented by R 5 or R 6 may be, for example, methyl, etc., and the substituent(s) thereof may be one or more (preferably 1 to 3) and includes, for example, hydroxyl, etc. .
- the nitrogen-containing aliphatic 5- to 6- membered heterocycle moiety of the "optionally substituted nitrogen-containing aliphatic 5- to 6- membered heterocyclic group" formed by combining R 5 and R 5 together with the adjacent nitrogen atom may be, for example, 1- pyrrolidinyl, 1-piperidyl, 1-piperazinyl, morpholin-4-yl, etc. Among them, 1-pyrrolidinyl, 1-piperidyl and 1-piperazinyl are preferable, and particularly 1-pyrrolidinyl is preferable.
- the substituent(s) of the "optionally substituted nitrogen- containing aliphatic 5- to 6 -membered heterocyclic group" may be one or more (preferably 1 to 3), and includes, for example, a lower alkyl group (e.g., methyl, etc.) or the like.
- the lower alkyl represented by R 7 may be methyl, etc.
- the preferred compounds of the compounds [I] of the present invention are the group of compounds having a chemical structure of the formula [Ia]:
- compounds are those wherein R is .
- Specifically preferred compounds are the free form of the compounds described in Examples hereinafter or a pharmaceutically acceptable salt thereof.
- the compounds [I] of the present invention may be either in the free form or in the form of a pharmaceutically acceptable salt.
- the pharmaceutically acceptable salt includes, for example, a salt with an inorganic acid such as hydrochloride, sulfate, nitrate, phosphate and hydrobromide, and a salt with an organic acid such as acetate, fumarate, oxalate, citrate, methanesulfonate, benzenesulfonate, p-toluenesulfonate and maleate.
- the pharmaceutically acceptable salt thereof includes, for example, a salt with a base such as an alkali metal salt (e.g., sodium salt, potassium salt, etc.) and an alkaline earth metal salt (e.g., calcium salt, etc.).
- the desired compounds [I] of the present invention and a salt thereof include any of intramolecular salts or adduct or their solvates or hydrates as well.
- the desired compounds [I] of the present invention or a pharmaceutically acceptable salt thereof exhibit an excellent inhibitory activity on glycine transporter type 2: GlyT2, and said activity shows a high selectivity to GlyT2.
- the desired compounds [I] of the present invention or a pharmaceutically acceptable salt thereof show a higher inhibitory activity on glycine transporter type 2: GlyT2 in comparison with that on glycine transporter type 1: GIyTl (more particularly GIyTIb, etc.).
- the desired compounds [I] of the present invention and a pharmaceutically acceptable salt thereof exhibit various pharmacological effects through their inhibitory activity on GlyT2.
- the desired compounds [I] of the present invention and a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same as an active ingredient may be used for inhibition of GlyT2, and these compounds or the pharmaceutical compositions containing the same may be used for treatment or prophylaxis of a disease or condition which can be expected to be • i i
- GlyT2 inhibitors Compounds having an inhibitory activity on a transporting activity of GlyT2 (GlyT2 inhibitors) are considered to elevate a glycine level in the glycinergic nerve terminals in the spinal cord through the GlyT2 inhibitory activity thereof when administered into a living body of a vertebrate.
- GlyT2 inhibitors are considered to be useful through their GlyT2 inhibitory activity, for example, as a muscle relaxant, an anesthetic, an analgesic, etc. for treatment of muscle spasticity, tinnitus, epilepsy, pain, etc. [Isaac et al., Bioorg. Med. Chem. Lett.
- GlyT2 inhibitors are considered to be useful through their GlyT2 inhibitory activity for treatment of urological disorders [WO 2005/94808 (Bayer Healthcare)].
- the desired compounds [I] of the present invention or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing the same as an active ingredient may be used for inhibition of a transporting activity of GlyT2, and also for activating glycinergic neuron in the spinal cord through its GlyT2 inhibitory activity by administration into a living body of a vertebrate.
- the desired compounds [I] of the present invention or a pharmaceutically acceptable salt thereof, or a pharmaceutical • composition containing the same as an active ingredient may preferably be used for treatment or prophylaxis of a disease or condition which can be expected to be improved by inhibition of GlyT2, namely for muscle spasticity, tinnitus, epilepsy, pain (particularly inflammatory pain and neuropathic pain, etc.) etc.
- a method for administration of an effective amount of the desired compound [I] of the present invention or a pharmaceutically acceptable salt thereof to a patient are also useful for the above- mentioned objects of the present invention and are inclusive in the present invention.
- the inhibitory activity on GlyT2 and the pharmacological effects of the compounds of the present invention can be confirmed by the following known methods or a similar method thereto.
- the inhibitory activity on glycine transporters can be detected by using cells expressing GlyT2 or GIyT 1.
- the selectivity of the compound to GlyT2 can be determined by comparing the inhibitory activity on GlyT2 with that on GIyTl.
- the detection of the inhibitory activity on glycine uptake by cells expressing GlyT2 or GIyTl can be carried out by a method disclosed in the literatures (Caulfield et al., J. Med. Chem., 2001, 44, 2679-2682; Williams et al., Anal. Biochem., 2003, 321, 31-37; Morrow et al., FEBS Letters, 1998, 439, 334-340; etc.).
- composition 15 pharmaceutically acceptable salt thereof as an active ingredient for medical purpose, it is used together with an inert carrier suitable for each administration route.
- an inert carrier suitable for each administration route for this purpose, it can be formulated into a conventional pharmaceutical preparation (tablets, granules, capsules, powders, solutions, suspensions, emulsions, injections, drops, etc.),
- the carrier includes, for example, any conventional pharmaceutically acceptable ones, such as binders (gum Alabicum, gelatin, sorbitol, polyvinylpyrrolidone, etc.), excipients (lactose, sucrose, corn starch, sorbitol, etc.), lubricants (magnesium stearate, talc, polyethylene glycol, etc.), disintegrators (potato starch, etc.).
- binders gaum Alabicum, gelatin, sorbitol, polyvinylpyrrolidone, etc.
- excipients lactose, sucrose, corn starch, sorbitol, etc.
- lubricants magnesium stearate, talc, polyethylene glycol, etc.
- disintegrators potato starch, etc.
- the administration route of the compound [I] of the present invention or a pharmaceutically acceptable salt thereof for medical use is not limited, and usual oral or parenteral routes (intravenous,
- intramuscular, subcutaneous, transdermal, transnasal, transmucosal, intestinal, etc. can be applied.
- the dosage of the compound [I] of the present invention or a pharmaceutically acceptable salt thereof for medical use can adequately be set forth within a range of an effective amount being capable of exhibiting the desired pharmacological effect in accordance with the potency and characteristics of the active compound.
- the dosage may vary depending on the administration routes, the age, the body weight and the conditions of the patient, and it is set forth adequately within a usual dosage range such as 0.001-300 mg/kg per day.
- the desired compound of the present invention [I] may be prepared by the following Method A or Method B, though it is not limited thereto. [Method A]
- the desired compound [I] of the present invention can be prepared, for example, as follows:
- a compound of the formula [11] (wherein Q is a protecting group for an amino group, and the other symbols are as defined above) or a salt thereof is reacted with a compound of the formula [12] (wherein the symbols are as defined above) or a salt thereof to give a compound of the formula [13-a] (wherein the symbols are as defined above) or a salt thereof.
- the protecting group for the amino group is removed from the compound [13-a] or a salt thereof to give a compound of the formula [13-b] (wherein the symbols are as defined above) or a salt thereof.
- any conventional protecting groups for an amino group such as t-butoxy- carbonyl group, benzyloxycarbonyl group, trifluoroacetyl group, 9- fluorenylmethyloxycarbonyl group, etc. can be suitably used.
- salts of the compounds [11], [12], [13-a], [13-b] and [14] for example, a salt with an inorganic acid such as hydrochloride and sulfate, an alkali metal salt such as sodium salt and potassium salt, an alkaline earth metal salt such as magnesium salt and calcium salt, etc. can be used.
- an inorganic acid such as hydrochloride and sulfate
- an alkali metal salt such as sodium salt and potassium salt
- an alkaline earth metal salt such as magnesium salt and calcium salt, etc.
- reaction of the compound [11] or a salt thereof and the compound [12] or a salt thereof may be carried out in a suitable solvent in the presence of a condensing agent, and further, if necessary, in the presence or absence of an additive and/ or a base.
- EDC l-(3-dimethylaminopropyl)-3- ethylcarbodiimide
- DCC diclohexyl- carbodiimide
- 1,3-diisopropylcarbodiimide DEPC (diethylphosphoryl cyanide)
- O-(7-azabenzotriazol- l-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate O-benzotriazol-l-yl-N,N, N', N'-tetramethyl- uronium hexafluorophosphate
- chloroformic acid esters e.g. ethyl chloroformate, isobutyl chloroformate, etc.
- 2,4,6-trichlorobenzoyl chloride carbonyldiimidazole, etc.
- an additive such as 1-hydroxybenzotriazole, l-hydroxy-7-azabenzotriazole, 3,4-dihydro-3 ⁇ hydroxy-4-oxo- 1,2,3- benzotriazine, 1-hydroxysuccinimide, dimethylaminopyridine, etc.
- an organic base e.g. triethylamine, diisopropyl- ethylamine, N-methylmorpholine, pyridine, dimethylaniline, dimethylaminopyridine, etc.
- an alkali metal carbonate e.g.
- the reaction preferably proceeds at -2O 0 C to 100 0 C, more preferably at 0 0 C to 40 0 C.
- the solvent may be any one which does not show an adverse affect upon the reaction, and for example, acetonitrile, N,N-dimethyl- formamide, tetrahydrofuran, diethyl ether, dioxane, ethyl acetate, toluene, methylene chloride, dichloroethane, chloroform, N,N-dimethyl- acetamide, 1 ,3-dimethyl-2-imidazolidinone, l-methyl-2-pyrrolidinone, 1,2-dimethoxyethane, xylene, or a mixture of two or more thereof can be suitably used.
- Removal of the protecting group for an amino group (Q) from the compound [13-a] or a salt thereof may be carried out in a conventional manner, for example, by an acid treatment using trifluoroacetic acid etc., by a base treatment or by a catalytic reduction, in a suitable solvent or without a solvent.
- reaction of the compound [13-b] or a salt thereof and the compound [14] or a salt thereof may be carried out in the same manner as in the reaction of the compound [11] or a salt thereof and the compound [12] or a salt thereof.
- the desired compound of the present invention [I] can also be prepared by the following method.
- a compound of the formula [15] (wherein Y represent a protecting group for a carboxyl group, and the other symbols are as defined above) or a salt thereof is reacted with the compound [14] or a salt thereof to give a compound of the formula [16-a] (wherein the symbols are as defined above) or a salt thereof.
- a compound of the formula [16-b] (wherein the symbols are as defined above) or a salt thereof is obtained.
- any conventional protecting groups for a carboxyl group such as methyl group, ben2yl group, allyl group, t-butyl group, etc. can be suitably used.
- salts of the compound [12] and [14] the same ones as mentioned above may be used, and as the salts of the compound [15], [16-a] and [16-b], a salt with an inorganic acid such, as hydrochloride and sulfate, or an alkali metal salt such as sodium salt and potassium salt can be used.
- the reaction of the above Method B is carried out as follows.
- the reaction of the compound [15] or a salt thereof and the compound [14] or a salt thereof may be carried out in the same manner as in the reaction of the compound [11] or a salt thereof and the compound [12] or a salt thereof.
- the removal of the protecting group for a carboxyl group (Y) from the compound [16-a] or a salt thereof may be carried out in a conventional manner, for example, by alkali-hydrolysis in a suitable solvent, by hydrogenolysis using a palladium catalyst in a suitable solvent or without a solvent, or by an acid treatment using trifluoro- acetic acid or hydrogen chloride etc.
- the reaction of the compound [16-b] or a salt thereof and the compound [12] or a salt thereof can be carried out in the same manner as in the reaction of the compound [11] or a salt thereof and the compound [12] or a salt thereof.
- the starting compounds in the above Method A and Method B can.be prepared by a known method and/or in the same manner as one described in Reference Examples as described hereinafter.
- the desired compound [I] prepared by the above Methods can be structurally converted into other desired compound [I] by a method disclosed in Examples as described hereinafter, a conventional method and/ or a combination thereof.
- the compound [I] of the present invention prepared as a'bove or a starting compound therefor may be isolated and purified either in the free form or in the form of a salt thereof.
- the salt may be prepared by a conventional method for preparation of a salt. Isolation and purification can be carried out by a conventional chemical procedure such as extraction, concentration, crystallization, filtration, recrystallization, various kinds of chromatography, etc.
- optical isomers such as racemic isomers, optically active isomers, diastereomers, etc. can be present alone or as mixture thereof.
- a stereochemical ⁇ pure isomer can be obtained by using a stereochemically pure starting compound or by separating an optical isomer according to the general separation process for racemic resolution.
- a mixture of diastereomers may be separated by a conventional method, for example, by fractional crystallization or chromatography, etc.
- MS-APCI m/z
- MS-ESI m/z
- MS-EI m/z
- Inhibitory activity on GlyT2 and GIyTl was examined by glycine uptake assays using cells expressing GlyT2 or GIyTl, as described in the literatures, Caulfield et al.(J. Med. Chem., 2001, 44, 2679-2682), Williams et al.(Anal. Biochem., 2003, 321, 31-37, etc.), and/ or Morrow et al. (FEBS Letters, 1998, 439: 334-340). Briefly, the assays were performed as follows.
- HEK 293 cells stably transfected with either human GlyT2 or human GIyTIb were used.
- the cells were grown in 96-well Cytostar- TTM scintillating microplates (20,000-40,000 cells/well) overnight before removal of culture medium and addition of HEPES buffered saline containing glycine (10 ⁇ M) labeled with 14 C and varying concentrations of test compounds.
- Plates were incubated at room temperature for 2-3 hours, and then, the plates were counted in a plate counter.
- ICso the concentration of test compound producing 50% inhibition
- Example 1.026 has specific inhibitory activity on GlyT2,where IC50 value in GlyT2 assay was lower than 10 nM, while IC50 value in GIyTl assay was .more than 100 times higher than that in GlyT2 assay.
- Example 2.001 listed in Table as described hereinafter was obtained.
- Example 2.011 In the same manner as in the above Example 2.001, the compounds of Examples 2.002 - 2.010 listed in Table as described hereinafter were obtained.
- Example 2.011 In the same manner as in the above Example 2.001, the compounds of Examples 2.002 - 2.010 listed in Table as described hereinafter were obtained.
- Example 2.011 In the same manner as in the above Example 2.001, the compounds of Examples 2.002 - 2.010 listed in Table as described hereinafter were obtained.
- Example 2.011 Example 2.011
- N-[(l, l-Dimethylethoxy)carbonyl]-O-methyl-L- serine (439 mg) and 4-amino- l-benzylpiperidine (381 mg) were treated in the same manner as in the above Example 1.001 (1) to obtain [( IS)-I -(methoxy- methyl)-2-oxo-2-[[l-(phenylmethyl)-4-piperidyl]amino]ethyl]-carbamic acid 1,1-dimethylethyl ester.
- Example 3.001 (1) To a solution of L-norvaline methyl ester hydrochloride (1.68 g), 4-hexyloxybenzoic acid (2.22 g) and 1-hydroxybenzotriazole (1.35 g) in chloroform (30 ml) were added l-(3-dimethylaminopropyl)-3-ethyl- carbodiimide hydrochloride (2.87 g) and triethylamine (2.8 ml) in this order, and the mixture was stirred at room temperature for 5 hours. To the reaction mixture was added water (30 ml), and the mixture was vigorously stirred for 10 minutes. The organic layer was collected, and the aqueous layer was further extracted with chloroform.
- Example 4.001 - 4.003 The compounds of Examples 3.002-3.003 listed in Table as described hereinafter were obtained in the same manner as in the above Example 3.001.
- Example 4.001 - 4.003 The compounds of Examples 3.002-3.003 listed in Table as described hereinafter were obtained in the same manner as in the above Example 3.001.
- Example 4.001 - 4.003 The compounds of Examples 3.002-3.003 listed in Table as described hereinafter were obtained in the same manner as in the above Example 3.001.
- Example 4.001 - 4.003 The compounds of Examples 3.002-3.003 listed in Table as described hereinafter were obtained in the same manner as in the above Example 3.001.
- Example 4.001 - 4.003 The compounds of Examples 3.002-3.003 listed in Table as described hereinafter were obtained in the same manner as in the above Example 3.001.
- Example 4.001 - 4.003 The compounds of Examples 3.002-3.003 listed in Table as described hereinafter were obtained in the same manner as in the above Example 3.001.
- Example 5.001 - 5.005 listed in Table as described hereinafter were obtained.
- Reference Examples 1.02-1.07 listed in Table as described hereinafter were obtained in the same manner as in the above Reference Example 1.01.
- Reference Example 1.08 (1) To a solution of 4-hydroxy-3,5-dimethylbenzoic acid (1.66 g) in N,N-dimethylacetamide (20 ml) were added potassium carbonate (5.52 g) and 1-bromohexane (4.2 ml) in this order, and the mixture was vigorously stirred at 100 0 C for 20 hours. The reaction solution was cooled to room temperature and poured into water, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated saline, and dried over anhydrous sodium sulfate.
- Reference Examples 1.09-1.10 listed in Table as described hereinafter were obtained by the same manner as in the above Reference Example 1.08.
- Reference Example 1.11 (1) A solution of 4-phenyl-l-butanol (1.50 g) and pyridine (3.2 ml) in methylene chloride (20 ml) was cooled in an ice bath, and thereto was added dropwise a solution of tosyl chloride (2.86 g) in methylene chloride (10 ml). The mixture was stirred for 2 hours, and washed with water, 10 % hydrochloric acid and saturated saline, and dried over anhydrous magnesium sulfate.
- Reference Example 2.05 (1) A suspension of sodium hydride (2.96 g) in diethyl ether was cooled in an ice bath, and thereto was added dropwise a solution of diethyl cyanomethylphosphonate (13.4 g) in diethyl ether (30 ml). Then, thereto was added dropwise a solution of cyclopentanone (5.65 g) in diethyl ether (10 ml), and the mixture was stirred for 10 minutes while cooling. The reaction mixture was warmed to room temperature, and then stirred for 12 hours.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Pyrrole Compounds (AREA)
Abstract
Norvaline derivative of the formula [I] or pharmaceutically acceptable salt thereof, method for preparing the same, pharmaceutical composition containing the same, and use of said compound for inhibiting transporting activity of glycine transporter type 2 (GlyT2). [wherein X is -CH2-, -O-, -S- or single bond; Ar is optionally substituted aryl or lower cycloalkyl; n is 0 to 2; R1 and R2 are (i) each is hydrogen or lower alkyl; (ii) R1 and R2 are combined to form lower alkylene; or (iii) R1 is hydrogen or lower alkyl and R2 is combined with R4 or R6 to form lower alkylene; R3 and R4 are (i) each is hydrogen or lower alkyl; (ii) R3 and R4 are combined to form lower alkylene; or (iii) R3 is hydrogen or lower alkyl and R4 is combined with R2 or R6 to form lower alkylene; R is or -OR7; R 5 and R6 are (i) each is optionally substituted lower alkyl, or hydrogen; (ii) R5 and R6 are combined to form aliphatic 5- to 6-membered heterocyclic group; or (iii) R5 is optionally substituted lower alkyl or hydrogen and R6 is combined with R2 or R4 to form lower alkylene; R7 is lower alkyl.
Description
DESCRIPTION
NORVALINE DERIVATIVE AND METHOD FOR PREPARATION THEREOF
TECHNICAL FIELD
The present invention relates to a novel norvaline derivative, which exhibits an excellent inhibitory activity on glycine transporter type 2: GlyT2 and is useful as a medicament, and a method for preparation the same and a use thereof.
BACKGROUND ART
Glycine is one of inhibitory neurotransmitters. Glycine shows an inhibitory activity on sensory nerves through strychnine-sensitive glycine receptors (ssGlyRs) in the spinal cord and the brain stem of a vertebrate.
It has been reported that a pain threshold is elevated by intrathecal administration of glycine, while it is lowered by intrathecal administration of strychnine having a glycine receptor antagonistic activity. Those results suggest that a pain threshold may be kept at a certain level or higher by stimulation of strychnine-sensitive glycine receptors by glycine in the spinal cord.
On the other hand, for many neurotransmitters, there are reuptake systems into cells. Specific transporters are participated in those reuptake systems, whereby concentration of the neurotransmitter is controlled.
As glycine-specific transporters, there have been known 'two classes such as glycine transporter type 1: GIyTl (including subtypes:
GIyTIa, GIyTIb, GIyTIc) and glycine transporter type 2: GlyT2 (including subtypes: GlyT2a, GlyT2b), and genes thereof were cloned one after another in the 1990s [Guastella et al., Proc. Natl. Acad. Sci.
USA5 1992, 89, 7189; Liu et al., FEBS Lett., 1992, 305, 110; Smith et al., Neuron, 1992, 8, 927; Borosky et al., Neuron, 1993, 10, 851].
Among these transporters for glycine, GIyT 1 is widely distributed in the central nervous system: CNS, and existing mainly in glia cells and it has been considered that GIyTl has a role to maintain a low concentration of glycine in an extracellular fluid.
On the contrary, GlyT2 exists locally in the brain stem and the spinal cord. GlyT2 takes a role in the reuptake system of glycine acting as a neurotransmitter in the brain stem and the spinal cord, and removes glycine from a synaptic space and inactivates glycinergic neuro-activity. Further, GlyT2 has the same distribution pattern as strychnine-sensitive glycine receptor: ssGlyR, and closely relates to the inhibitory system through strychnine-sensitive glycine receptors. Based upon this knowledge, it has been considered that the synaptic glycine level in the intrathecal space is elevated by inhibition of GlyT2 activity, and whereby the function of inhibitory neuron expressing ssGlyR is activated and then pain-related neurotransmission should be limited. Further, compounds which inhibit the transporting activity of GlyT2 (GlyT2 inhibitor) have been considered as being useful as a muscle relaxant, an anesthetic, an analgesic, etc. for treatment of muscle spasticity, tinnitus, epilepsy, neuropathic pain, etc. [Isaac et al., Bioorg. Med. Chem. Lett. 2001, 11,1371-1373; WO2003/ 10132 (Akzo Nobel); Caulfield et al., J. Med. Chem., 2001,44: 2679-2682; Ho et al., Bioorganic & Medicinal Chemistry Letters, 2004, 14, 545-548; Friauf et al., J. Comp. Neurol., 1999, 412, 17; Simpson et al., Neurochem. Res., 1996, 21, 1221; Huang et al., Neurol. Res., 2000, 22, 160; Gomeza et al., Curr. Opin. Drug Discovery Dev., 2003, 6, 675; Aragon., Eur. J. Pharmacol., 2003, 479, 249-262].
Further, it has actually been reported that a compound which inhibits the transporting activity of GlyT2 (GlyT2 inhibitor) shows an effect of improving hyperalgesia by increasing a pain threshold in
neuropathic pain models [Houghton et al., 31st Society of Neuroscience Meeting Abstracts 2001, 27 (Abs 283.1)] .
Further, GlyT2 inhibitors are considered as being useful for treatment of urological disorders [WO 2005/94808 (Bayer Healthcare)]. Consequently, GlyT2 inhibitors have been expected to be developed as an excellent medicament. Particularly, neuropathic pain syndromes are difficult to be cured, and available medicaments for neuropathic pain such as μ-Opioid, etc. often show side effects to the central nervous system, and thus, it has strongly been demanded to develop an excellent medicament therefor.
As to compounds which inhibit the transportation activity of GlyT2 (GlyT2 inhibitor), the following reports have been found.
For instance, amino acid derivatives having GlyT2 inhibiting activity are disclosed in the literature of Isaac et al. (Isaac et al, Bioorg. Med. Chem. Lett. 2001, 11, 1371-1373) (NPS); benzamide derivatives such as N-[(l-dimethylaminocycloalkyl)methyl]benzamide derivatives, 2- (aminomethyl) benzamide derivatives, etc. are disclosed in WO 2003/ 10132 (Akzo Nobel), the literature of Caulfield et al. (Caulfield et al., Journal of Medicinal Chemistry, 2001, 44, 2679-2682) and the literature of Ho et al. (Ho et al., Bioorganic & Medicinal Chemistry Letters, 2004, 14, 545-548).
Further, α, β and γ amino acid derivatives are disclosed in the literatures of Wolin et al. (Wolin et al., Bioorganic 8B Medicinal Chemistry, 2004, 12:4477-4492; Wolin et al., Bioorganic & Medicinal Chemistry, 2004, 12:4493-4509) and WO 2005/044810 (Janssen Pharmaceutica).
Still further, aryl piperidine amide derivatives are disclosed in the literatures of Wolin et al. (Wolin et al., Bioorganic 85 Medicinal Chemistry, 2004, 12:4511-4532) and WO 2005/021525 (Janssen Pharmaceutica) .
DISCLOSURE OF INVENTION
The present invention provides a novel compound having an excellent inhibitory activity on glycine transporter type 2: GlyT2, a method for preparation thereof, and a use of the same and a pharmaceutical composition containing said compound etc.
The present inventors have intensively studied and have found a norvaline derivative having an excellent inhibitory activity on glycine transporter type 2: GlyT2 to accomplish the present invention.
Namely, the present invention relates to a norvaline derivative of the formula [I]:
X is -CH2-, -O-, -S- or a single bond;
Ar is an optionally substituted aryl or an optionally substituted lower cycloalkyl; n is an integer of 0 to 2;
R1 and R2 are the following (i), (ii) or (iii):
(i) each is independently a hydrogen atom or a lower alkyl; (ii) R1 and R2 are combined together to form a lower alkylene; or (iϋ) R1 is a hydrogen atom or a lower alkyl and R2 is combined
R3 and R4 are the following (i), (ii) or (iii):
(i) each is independently a hydrogen atom or a lower alkyl; (ii) R3 and R4 are combined together to form a lower alkylene; or (ϋi) R3 is a hydrogen atom or a lower alkyl and R4 is combined
together with R2 or R6 to form a lower alkylene, when R is R6 ;
R5 and R6 are the following (i), (ii) or (iii):
(i) each is independently a lower alkyl optionally substituted with hydroxyl group(s), or a hydrogen atom;
(ii) R5 and R5 are combined together with the adjacent nitrogen atom to form an optionally substituted nitrogen-containing aliphatic 5- to 6- membered heterocyclic group;
(iii) R5 is a lower alkyl optionally substituted with hydroxyl group(s), or a hydrogen atom, and R6 is combined together with R2 or R4 to form a lower alkylene; R7 is a lower alkyl; provided that when R5 and R6 are combined together with the adjacent nitrogen atom to form a morpholine ring, then Ar has at least one substituent other than halogen atom, methoxy or phenyl; and when R is -OR7 and X is a single bond, then Ar is an optionally substituted phenyl, an optionally substituted naphthyl or an optionally substituted lower cycloalkyl], or a pharmaceutically acceptable salt thereof. Further, the present invention relates to a method for preparation of the above compound [I] or a pharmaceutically acceptable salt thereof.
Further, the present invention relates to a pharmaceutical composition containing the above compound [I] or a pharmaceutically acceptable salt thereof as an active ingredient.
Further, the present invention relates to a method for treatment or prophylaxis of a disease or condition, which comprises administering an effective amount of the above compound [I] or a pharmaceutically acceptable salt thereof to a patient.
Still further, the present invention relates to a use of the above compound [I] or a pharmaceutically acceptable salt thereof for manufacture of a medicament.
Still further, the present invention relates to a use of the above compound [I] or a pharmaceutically acceptable salt thereof for the inhibition of a transporting activity of glycine transporter type 2 (GlyT2) .
The desired compound [I] of the present invention or a pharmaceutically acceptable salt thereof exhibits an excellent inhibitory activity on glycine transporter type 2: GlyT2. The pharmaceutical composition containing the desired compound of the present invention is useful as an active ingredient in a medicament for treatment or prophylaxis of a disease or condition (such as pain) which may be expected to be improved by inhibition of glycine transporter type 2: GlyT2.
BEST MODE FOR CARRYING OUT THE INVENTION
The desired compound [I] of the present invention may have optical isomers, and the present invention includes any of these isomers and also a mixture thereof. - In the present invention, the lower alkyl group, the lower alkylthio group, the lower alkylsulfonyl group, the lower alkoxy group, and the lower alkylamino group include a straight chain or branched chain groups having 1-6 carbon atoms (Ci-β), particularly ones having
1-4 carbon atoms (C 1-4). The lower alkanoyl group and the lower alkanoylamino group include ones having 2-7 carbon atoms (C2-7), particularly ones having 2-
5 carbon atoms (C2-5).
The lower alkanoyl group includes either one of a lower alkyl-
CO- or a lower cycloalkyl-CO-. The lower cycloalkyl group and the lower cycloalkenyl group include ones having 3-8 carbon atoms (C3-8), particularly ones having 3-
6 carbon atoms (C3-6) .
The lower alkylene group includes a straight chain or branched chain groups having 1-6 carbon atoms (Ci-β), particularly ones having 1-4 carbon atoms (Ci-4).
5 The lower alkenyl group and the lower alkenylene group include ones having 2-7 carbon atoms (C2-7), particularly ones having 2-5 carbon atoms (C2-5).
Further, the halogen atom includes, for example, a fluorine atom, a chlorine atom, a bromine atom or an iodine atom.
10 The optionally substituted amino group includes, for example, unsubstituted amino group and mono- or di-substituted non-cyclic amino group, and further includes cyclic amino group (e.g., 1- pyrrolidinyl, 1-piperidyl, 1-piperazinyl, morpholin-4-yl, etc.).
In the desired compound [I] of the present invention, the aryl
15 moiety of the "optionally substituted aryl" represented by Ar includes a monocyclic or a bicyclic aryl, including monocyclic or bicyclic aromatic hydrocarbon group, and also including monocyclic or bicyclic aromatic heterocyclic group (heteroaryl). Said aryl specifically includes, for example, phenyl and naphthyl etc.
20 - The lower cycloalkyl moiety of the "optionally substituted lower cycloalkyl" represented by Ar includes ones having 3-8 carbon atoms (C3-8), more preferably ones having 3-6 carbon atoms (C3-6). Said lower cycloalkyl specifically includes, for example, cyclohexyl etc.
The substituent(s) of the "optionally substituted aryl" or
25 "optionally substituted lower cycloalkyl" represented by Ar may be one or more (preferably 1 to 3), and includes, for example, halogen atom (such as Cl, F, etc.); nitro group; cyano group; hydroxyl group; " optionally substituted amino group [e.g., amino group optionally substituted with 1 or 2 substituent(s) selected from lower alkyl and
30. formyl, etc.]; C 1.7 alkyl ; optionally substituted Ci-12 alkoxy [e.g., lower alkoxy optionally substituted with phenyl which is optionally
substituted with group(s) selected from halogen atom, lower alkyl and halo(lower)alkyl, etc.]; lower cycloalkoxy; lower alkylthio group; optionally substituted phenyl [e.g., phenyl optionally substituted with group(s) selected from halogen atom, lower alkyl and lower alkoxy, etc.]; optionally substituted piperidyl [e.g., 1-piperidyl optionally substituted with group(s) selected from lower alkyl and phenyl, etc.]; optionally substituted phenoxy [e.g., phenoxy optionally substituted with halogen atom(s), etc.]; and the like.
The lower alkyl represented by R1, R2, R3 or R4 may be methyl, etc.
The lower alkylene formed by combining R1 and R2 or R3 and R4 may be, for example, n-propane-l,3-diyl, n-butane-l,4-diyl, etc.
The lower alkylene formed by combining R2 and R4, R2 and R6, or R4 and R6 may be, for example, n-propane-l,3-diyl, n-butane-l,4-diyl, etc.
The lower alkyl moiety of the "optionally substituted lower alkyl" represented by R5 or R6 may be, for example, methyl, etc., and the substituent(s) thereof may be one or more (preferably 1 to 3) and includes, for example, hydroxyl, etc. . The nitrogen-containing aliphatic 5- to 6- membered heterocycle moiety of the "optionally substituted nitrogen-containing aliphatic 5- to 6- membered heterocyclic group" formed by combining R5 and R5 together with the adjacent nitrogen atom may be, for example, 1- pyrrolidinyl, 1-piperidyl, 1-piperazinyl, morpholin-4-yl, etc. Among them, 1-pyrrolidinyl, 1-piperidyl and 1-piperazinyl are preferable, and particularly 1-pyrrolidinyl is preferable.
The substituent(s) of the "optionally substituted nitrogen- containing aliphatic 5- to 6 -membered heterocyclic group" (the substituent on the ring) may be one or more (preferably 1 to 3), and includes, for example, a lower alkyl group (e.g., methyl, etc.) or the like. The lower alkyl represented by R7 may be methyl, etc.
The preferred compounds of the compounds [I] of the present invention are the group of compounds having a chemical structure of the formula [Ia]:
Besides, among the compounds [I] of the present invention or the above-mentioned groups of compounds, other preferred groups of compounds are ones wherein X is -CH2-.
Further, among the compounds [I] of the present invention or the above-mentioned groups of compounds, other preferred groups of compounds are ones wherein X is -O- .
Further, among the compounds [I] of the present invention or the above-mentioned groups of compounds, other preferred groups of compounds are ones wherein X is -S-. Further, among the compounds [I] of the present invention or the above-mentioned groups of compounds, other preferred groups of compounds are ones wherein X is a single bond.
Among the compounds [I] of the present invention or the above- mentioned group of compounds, further preferred group of compounds are ones wherein Ar is a group selected from a substituted phenyl and a substituted naphthyl.
Still further, among the compounds [I] of the present invention or the above-mentioned group of compounds, preferred group of
compounds are those wherein R is
. Specifically preferred compounds are the free form of the compounds described in Examples hereinafter or a pharmaceutically acceptable salt thereof.
The compounds [I] of the present invention may be either in the free form or in the form of a pharmaceutically acceptable salt.
The pharmaceutically acceptable salt includes, for example, a salt with an inorganic acid such as hydrochloride, sulfate, nitrate, phosphate and hydrobromide, and a salt with an organic acid such as acetate, fumarate, oxalate, citrate, methanesulfonate, benzenesulfonate, p-toluenesulfonate and maleate. When the compound of the present invention has a substituent such as a carboxyl group, the pharmaceutically acceptable salt thereof includes, for example, a salt with a base such as an alkali metal salt (e.g., sodium salt, potassium salt, etc.) and an alkaline earth metal salt (e.g., calcium salt, etc.).
The desired compounds [I] of the present invention and a salt thereof include any of intramolecular salts or adduct or their solvates or hydrates as well. The desired compounds [I] of the present invention or a pharmaceutically acceptable salt thereof exhibit an excellent inhibitory activity on glycine transporter type 2: GlyT2, and said activity shows a high selectivity to GlyT2. Namely, the desired compounds [I] of the present invention or a pharmaceutically acceptable salt thereof show a higher inhibitory activity on glycine transporter type 2: GlyT2 in comparison with that on glycine transporter type 1: GIyTl (more particularly GIyTIb, etc.).
Further, the desired compounds [I] of the present invention and a pharmaceutically acceptable salt thereof exhibit various pharmacological effects through their inhibitory activity on GlyT2. Thus, the desired compounds [I] of the present invention and a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same as an active ingredient may be used for inhibition of GlyT2, and these compounds or the pharmaceutical compositions containing the same may be used for treatment or prophylaxis of a disease or condition which can be expected to be
• i i
improved by inhibition of GlyT2.
Compounds having an inhibitory activity on a transporting activity of GlyT2 (GlyT2 inhibitors) are considered to elevate a glycine level in the glycinergic nerve terminals in the spinal cord through the GlyT2 inhibitory activity thereof when administered into a living body of a vertebrate. Thus, GlyT2 inhibitors are considered to be useful through their GlyT2 inhibitory activity, for example, as a muscle relaxant, an anesthetic, an analgesic, etc. for treatment of muscle spasticity, tinnitus, epilepsy, pain, etc. [Isaac et al., Bioorg. Med. Chem. Lett. 2001, 11,1371-1373; WO2003/ 10132 (Akzo Nobel); Caulfield et al., J. Med. Chem., 2001,44:2679-2682; Ho et al., Bioorganic & Medicinal Chemistry Letters, 2004, 14, 545-548; Friauf et al., J. Comp. Neurol., 1999, 412, 17; Simpson et al., Neurochem. Res., 1996, 21, 1221; Huang et al., Neurol. Res., 2000, 22, 160; Gomeza et al., Curr. Opin. Drug Discovery Dev., 2003, 6, 675; Aragon., Eur. J. Pharmacol., 2003, 479, 249-262].
Further, GlyT2 inhibitors are considered to be useful through their GlyT2 inhibitory activity for treatment of urological disorders [WO 2005/94808 (Bayer Healthcare)]. - Thus, the desired compounds [I] of the present invention or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing the same as an active ingredient may be used for inhibition of a transporting activity of GlyT2, and also for activating glycinergic neuron in the spinal cord through its GlyT2 inhibitory activity by administration into a living body of a vertebrate. Further, the desired compounds [I] of the present invention or a pharmaceutically acceptable salt thereof, or a pharmaceutical • composition containing the same as an active ingredient may preferably be used for treatment or prophylaxis of a disease or condition which can be expected to be improved by inhibition of GlyT2, namely for muscle spasticity, tinnitus, epilepsy, pain (particularly inflammatory pain and
neuropathic pain, etc.) etc.
A method for administration of an effective amount of the desired compound [I] of the present invention or a pharmaceutically acceptable salt thereof to a patient are also useful for the above- mentioned objects of the present invention and are inclusive in the present invention.
Further, an use of the desired compound [I] of the present invention or a pharmaceutically acceptable salt thereof for manufacture of a medicament are also useful for the above-mentioned objects of the present invention and are inclusive in the present invention.
The inhibitory activity on GlyT2 and the pharmacological effects of the compounds of the present invention can be confirmed by the following known methods or a similar method thereto.
The inhibitory activity on glycine transporters (GlyT2 or GIyTl) can be detected by using cells expressing GlyT2 or GIyT 1. The selectivity of the compound to GlyT2 can be determined by comparing the inhibitory activity on GlyT2 with that on GIyTl.
The detection of the inhibitory activity on glycine uptake by cells expressing GlyT2 or GIyTl can be carried out by a method disclosed in the literatures (Caulfield et al., J. Med. Chem., 2001, 44, 2679-2682; Williams et al., Anal. Biochem., 2003, 321, 31-37; Morrow et al., FEBS Letters, 1998, 439, 334-340; etc.).
The effect on inflammatory pain can be detected in the following experimental systems using the mouse or rat. ■ Formalin test:
(Bannon et al., J. Pharmacol. Exp. Ther., 1998, 285, 787-794)
• Inflammatory pain model:
(Taniguchi et al., Br. J. Pharmacol., 1997, 122, 809-812; Clayton et al., Pain, 2002, 96, 253-260; Walker et al., J. Pharmacol. Exp. Ther., 2003, 304, 56-62)
• Model of hyperalgesia after thermal injury:
(Nozaki-Taguchi et al, Neurosci. Lett., 1998, 254, 25-28)
• Model of incisional pain:
(Brennan et al., Pain, 1996, 64, 493-501)
The effect on neuropathic pain can be detected in the following 5 experimental systems using the mouse or rat. •Chronic constriction injury model:
(Bennett et al., Pain, 1988, 33, 87-107)
• Segmental spinal nerve ligation model:
(Kim et al., Pain, 1992, 50, 355-363) 10 ' Partial sciatic nerve ligation model:
(Seltzers et al., Pain, 1990, 43, 205-218)
• Diabetic neuropathy model:
(Bannon et al., Brain Res., 1998, 801, 158-163)
In case of using the compound [I] of the present invention or a
15 pharmaceutically acceptable salt thereof as an active ingredient for medical purpose, it is used together with an inert carrier suitable for each administration route. For this purpose, it can be formulated into a conventional pharmaceutical preparation (tablets, granules, capsules, powders, solutions, suspensions, emulsions, injections, drops, etc.),
20 and used. The carrier includes, for example, any conventional pharmaceutically acceptable ones, such as binders (gum Alabicum, gelatin, sorbitol, polyvinylpyrrolidone, etc.), excipients (lactose, sucrose, corn starch, sorbitol, etc.), lubricants (magnesium stearate, talc, polyethylene glycol, etc.), disintegrators (potato starch, etc.). In case of
25 injections and drops, it can be formulated with using distilled water for injection, physiological saline, an aqueous glucose solution, etc.
The administration route of the compound [I] of the present invention or a pharmaceutically acceptable salt thereof for medical use is not limited, and usual oral or parenteral routes (intravenous,
30. intramuscular, subcutaneous, transdermal, transnasal, transmucosal, intestinal, etc.) can be applied.
The dosage of the compound [I] of the present invention or a pharmaceutically acceptable salt thereof for medical use can adequately be set forth within a range of an effective amount being capable of exhibiting the desired pharmacological effect in accordance with the potency and characteristics of the active compound. The dosage may vary depending on the administration routes, the age, the body weight and the conditions of the patient, and it is set forth adequately within a usual dosage range such as 0.001-300 mg/kg per day.
The desired compound of the present invention [I] may be prepared by the following Method A or Method B, though it is not limited thereto. [Method A]
[13-b] [I]
The desired compound [I] of the present invention can be prepared, for example, as follows:
At first, a compound of the formula [11] (wherein Q is a protecting group for an amino group, and the other symbols are as defined above) or a salt thereof is reacted with a compound of the formula [12] (wherein the symbols are as defined above) or a salt thereof to give a compound of the formula [13-a] (wherein the symbols are as defined above) or a salt thereof.
The protecting group for the amino group is removed from the compound [13-a] or a salt thereof to give a compound of the formula [13-b] (wherein the symbols are as defined above) or a salt thereof.
The compound [13-b] or a salt thereof is reacted with a compound of the formula [14] (wherein the symbols are as defined above) or a salt thereof, followed by converting the resultant into a pharmaceutically acceptable salt thereof, if necessary, to give the desired compound of the formula [I].
As the protecting group for an amino group of Q, any conventional protecting groups for an amino group such as t-butoxy- carbonyl group, benzyloxycarbonyl group, trifluoroacetyl group, 9- fluorenylmethyloxycarbonyl group, etc. can be suitably used.
As the salts of the compounds [11], [12], [13-a], [13-b] and [14], for example, a salt with an inorganic acid such as hydrochloride and sulfate, an alkali metal salt such as sodium salt and potassium salt, an alkaline earth metal salt such as magnesium salt and calcium salt, etc. can be used.
The reaction of the above Method A is carried out as follows.
The reaction of the compound [11] or a salt thereof and the compound [12] or a salt thereof may be carried out in a suitable solvent in the presence of a condensing agent, and further, if necessary, in the presence or absence of an additive and/ or a base.
As the condensing agent, EDC (l-(3-dimethylaminopropyl)-3- ethylcarbodiimide) or a hydrochloride thereof, DCC (dicyclohexyl- carbodiimide), 1,3-diisopropylcarbodiimide, DEPC (diethylphosphoryl cyanide), O-(7-azabenzotriazol- l-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate, O-benzotriazol-l-yl-N,N, N', N'-tetramethyl- uronium hexafluorophosphate, chloroformic acid esters (e.g. ethyl chloroformate, isobutyl chloroformate, etc.), 2,4,6-trichlorobenzoyl chloride, carbonyldiimidazole, etc. can be suitably used.
Further, in order to accelerate the reaction or to prevent a side
reaction (e.g. racemization), an additive such as 1-hydroxybenzotriazole, l-hydroxy-7-azabenzotriazole, 3,4-dihydro-3~hydroxy-4-oxo- 1,2,3- benzotriazine, 1-hydroxysuccinimide, dimethylaminopyridine, etc. can be added together with the above condensing agent. As the base, an organic base (e.g. triethylamine, diisopropyl- ethylamine, N-methylmorpholine, pyridine, dimethylaniline, dimethylaminopyridine, etc.), an alkali metal carbonate (e.g. sodium carbonate, potassium carbonate, etc.), an alkali metal (e.g. sodium hydroxide, potassium hydroxide, etc.), etc. can be suitably used. The reaction preferably proceeds at -2O0C to 1000C, more preferably at 00C to 400C.
The solvent may be any one which does not show an adverse affect upon the reaction, and for example, acetonitrile, N,N-dimethyl- formamide, tetrahydrofuran, diethyl ether, dioxane, ethyl acetate, toluene, methylene chloride, dichloroethane, chloroform, N,N-dimethyl- acetamide, 1 ,3-dimethyl-2-imidazolidinone, l-methyl-2-pyrrolidinone, 1,2-dimethoxyethane, xylene, or a mixture of two or more thereof can be suitably used.
Removal of the protecting group for an amino group (Q) from the compound [13-a] or a salt thereof may be carried out in a conventional manner, for example, by an acid treatment using trifluoroacetic acid etc., by a base treatment or by a catalytic reduction, in a suitable solvent or without a solvent.
The reaction of the compound [13-b] or a salt thereof and the compound [14] or a salt thereof may be carried out in the same manner as in the reaction of the compound [11] or a salt thereof and the compound [12] or a salt thereof.
[Method B]
[1 6-b] [I]
The desired compound of the present invention [I] can also be prepared by the following method. At first, a compound of the formula [15] (wherein Y represent a protecting group for a carboxyl group, and the other symbols are as defined above) or a salt thereof is reacted with the compound [14] or a salt thereof to give a compound of the formula [16-a] (wherein the symbols are as defined above) or a salt thereof. By removing the protecting group for a carboxyl group from the compound [16-a] or a salt thereof, a compound of the formula [16-b] (wherein the symbols are as defined above) or a salt thereof is obtained.
The compound [16-b] or a salt thereof is reacted with the above compound [12] or a salt thereof, followed by converting the resultant into a pharmaceutically acceptable salt thereof, if necessary, to give the desired compound of the formula [I].
As the protecting group for a carboxyl group of Y, any conventional protecting groups for a carboxyl group such as methyl group, ben2yl group, allyl group, t-butyl group, etc. can be suitably used.
As the salts of the compound [12] and [14], the same ones as mentioned above may be used, and as the salts of the compound [15],
[16-a] and [16-b], a salt with an inorganic acid such, as hydrochloride and sulfate, or an alkali metal salt such as sodium salt and potassium salt can be used.
The reaction of the above Method B is carried out as follows. The reaction of the compound [15] or a salt thereof and the compound [14] or a salt thereof may be carried out in the same manner as in the reaction of the compound [11] or a salt thereof and the compound [12] or a salt thereof.
The removal of the protecting group for a carboxyl group (Y) from the compound [16-a] or a salt thereof may be carried out in a conventional manner, for example, by alkali-hydrolysis in a suitable solvent, by hydrogenolysis using a palladium catalyst in a suitable solvent or without a solvent, or by an acid treatment using trifluoro- acetic acid or hydrogen chloride etc. The reaction of the compound [16-b] or a salt thereof and the compound [12] or a salt thereof can be carried out in the same manner as in the reaction of the compound [11] or a salt thereof and the compound [12] or a salt thereof.
The starting compounds in the above Method A and Method B can.be prepared by a known method and/or in the same manner as one described in Reference Examples as described hereinafter.
Further, the desired compound [I] prepared by the above Methods (Method A or Method B) can be structurally converted into other desired compound [I] by a method disclosed in Examples as described hereinafter, a conventional method and/ or a combination thereof.
The compound [I] of the present invention prepared as a'bove or a starting compound therefor may be isolated and purified either in the free form or in the form of a salt thereof. The salt may be prepared by a conventional method for preparation of a salt. Isolation and purification can be carried out by a conventional chemical procedure
such as extraction, concentration, crystallization, filtration, recrystallization, various kinds of chromatography, etc.
In the compound of the present invention, optical isomers such as racemic isomers, optically active isomers, diastereomers, etc. can be present alone or as mixture thereof. A stereochemical^ pure isomer can be obtained by using a stereochemically pure starting compound or by separating an optical isomer according to the general separation process for racemic resolution. A mixture of diastereomers may be separated by a conventional method, for example, by fractional crystallization or chromatography, etc.
The present invention is illustrated in more details by Examples, but it should not be construed to be limited thereto.
In Table A, Table B, Table C, Table D, Table E and Table of Reference Examples as described hereinafter, the chemical structures and the physical properties, etc. of the compounds of Examples and Reference Examples are shown.
In Tables, MS-APCI (m/z), MS- ESI (m/z) and MS-EI (m/z) indicate mass spectrometric data.
(APCI: atmospheric pressure chemical ionization mass spectrum, ESI: electrospray ionization mass spectrum, EI: electron ionization mass spectrum).
Additionally, in ,the specification, the meanings of abbreviations are as follows:
[Me]: a methyl group, [Et]: an ethyl group,
[Bu]: a butyl group,
[Boc]: a tert-butoxycarbonyl group,
[Ts]: a p-toluenesulfonyl group.
Experiment 1 Glycine uptake assay (GlyT2 and GIyTl assay)
Inhibitory activity on GlyT2 and GIyTl was examined by glycine
uptake assays using cells expressing GlyT2 or GIyTl, as described in the literatures, Caulfield et al.(J. Med. Chem., 2001, 44, 2679-2682), Williams et al.(Anal. Biochem., 2003, 321, 31-37, etc.), and/ or Morrow et al. (FEBS Letters, 1998, 439: 334-340). Briefly, the assays were performed as follows.
HEK 293 cells stably transfected with either human GlyT2 or human GIyTIb were used. The cells were grown in 96-well Cytostar- T™ scintillating microplates (20,000-40,000 cells/well) overnight before removal of culture medium and addition of HEPES buffered saline containing glycine (10 μM) labeled with 14C and varying concentrations of test compounds.
Plates were incubated at room temperature for 2-3 hours, and then, the plates were counted in a plate counter.
Data were analyzed by the sigmoid dose-response curve fitting to produce ICso (the concentration of test compound producing 50% inhibition) values.
As a result of the assay, it was shown that the compound of Example 1.026 has specific inhibitory activity on GlyT2,where IC50 value in GlyT2 assay was lower than 10 nM, while IC50 value in GIyTl assay was .more than 100 times higher than that in GlyT2 assay.
EXAMPLES Example 1.001
(1) To a solution of tert-butoxycarbonyl-L-norvaline (1.50 g), l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (1.99 g) and 1-hydroxybenzotriazole (933 mg) in chloroform (20 ml) were added N,N-dimethylethylenediamine (0.758 ml) and triethylamine (0.962 ml) in this order, and the mixture was stirred at room temperature for 16 hours. To the reaction mixture was added water (30 ml), and the reaction mixture was stirred vigorously for 10 minutes, and the organic layer was separated. The aqueous layer was further extracted with chloroform. The organic layers were combined and washed with 1 %
aqueous potassium carbonate solution and saturated saline, and dried over anhydrous sodium sulfate, followed by removing the solvent under reduced pressure. The residue was purified by silica gel column chromatography [solvent: methanol-chloroform (1: 10)] to obtain N2-(tert- butoxycarbonyl)-N1-[2-(dimethylamino)ethyl]-L-norvalinamide (1.67 g). MS-APCI(m/z): 288 [M+H]+
(2) To a solution of the compound (1.67 g) obtained in the above (1) in dioxane (5 ml) was added 4N solution of hydrogen chloride in dioxane (5 ml), and the mixture was stirred at room temperature for 2 hours. To the reaction mixture was added diethyl ether, and the mixture was stirred at room temperature for further 30 minutes. The precipitated powder was collected by filtration and dried under reduced pressure to obtain N1-[2-(dimethylamino)ethyl]-L-norvalinamide dihydrochloride ( 1.5 g) . MS-APCI(m/z): 188 [M+H]+
(3) To a solution of the compound (1.0 g) obtained in the above (2), 4-hexyloxybenzoic acid (854 mg) and 1-hydroxybenzotriazole (513 mg) in N,N-dimethylformamide (20 ml) were added l-(3-dimethyl- aminopropyl)-3-ethylcarbodiimide hydrochloride (1.09 g) and triethyl- amine (2.1 ml) in this order, and the mixture was stirred at room temperature for 15 hours. To the reaction mixture was added water (100 ml), and the mixture was stirred vigorously for 10 minutes, and extracted with ethyl acetate. The organic layer was washed with water, 1 % aqueous potassium carbonate solution and saturated saline, and dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography [solvent: ammonium hydroxide-methanol-chlof oform (1:2:20)] and recrystallized from isopropyl ether to obtain N-[(lS)-l-[[[2- (dimethylamino)ethyl]amino]carbonyl]butyl]-4-(hexyloxy)benzamide (845 mg, the compound of Example 1.001 listed in Table as described hereinafter).
Examples 1.002- 1.035
In the same manner as in the above Example 1.001, the compounds of Examples 1.002- 1.035 listed in Table as described hereinafter were obtained. Example 1.036
(1) In the same manner as in Example 1.001, N-[(1S)- 1-[[[1- (dimethylamino) cyclopentyl] methyl] amino] carbonyl] butyl] -4-(hexyloxy) - 3-(nitro) benzamide was obtained.
(2) To a solution of the compound (207 mg) obtained in the above (1) in methanol (12 ml) was added 10 % palladium on activated carbon
( 100 mg). The mixture was subjected to catalytic hydrogenation under atmospheric pressure. After 5 hours, the catalyst was removed by filtration, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography [NH] [solvent: methanol-chloroform (1: 10)] to obtain 3-amino-N-[(lS)- l-[[[l- (dimethylamino) cyclopentyl] methyl]amino] carbonyl]butyl-4- (hexyloxy) - benzamide (187 mg, the compound of Example 1.036 listed in Table as described hereinafter) . Examples 1.037 - 1.081 - In the same manner as in the above Example 1.001, the compounds of Examples 1.037 - 1.081 listed in Table as described hereinafter were obtained. Example 1.082
To a solution of N-[(lS)-l-[[[l-(dimethylamino)cyclopentyl]- methyl]aminocarbonyl]butyl]-4-hexyloxy-3-(methoxymethoxy)benzamide (17 mg) (obtained in the same manner as in the above Example 1.001) in dioxane (3 ml) was added 4N solution of hydrogen chloride in dioxane (3 ml), and the mixture was stirred for 2 hours. The reaction mixture was concentrated under reduced pressure, and the residue was washed with diethyl ether to obtain N-[(lS)-l-[[[l-(dimethylamino)cyclopentyl]- methyl]aminocarbonyl]butyl]-4-hexyloxy-3-hydroxybenzamide
hydrochloride (15 mg, the compound of Example 1.082 listed in Table as described hereinafter). Example 2.001
In the same manner as in the above Example 1.001 using N- [(1, 1 -dimethylethoxyJcarbonylJ-O-methyl-L- serine instead of tert- butoxycarbonyl-L-norvaline as a starting compound, the compound of Example 2.001 listed in Table as described hereinafter was obtained.
Examples 2.002 - 2.010
In the same manner as in the above Example 2.001, the compounds of Examples 2.002 - 2.010 listed in Table as described hereinafter were obtained. Example 2.011
(1) N-[(l, l-Dimethylethoxy)carbonyl]-O-methyl-L- serine (439 mg) and 4-amino- l-benzylpiperidine (381 mg) were treated in the same manner as in the above Example 1.001 (1) to obtain [( IS)-I -(methoxy- methyl)-2-oxo-2-[[l-(phenylmethyl)-4-piperidyl]amino]ethyl]-carbamic acid 1,1-dimethylethyl ester.
MS-APCI(m/z): 392[M+H]+
(2) To a solution of the compound (815 mg) obtained in the above (1) in methanol (15 ml), was added 20% palladium hydroxide on activated carbon (250 mg). The mixture was stirred vigorously for 2 hours under hydrogen atmosphere. The catalyst was removed from the reaction mixture by filtration, and the filtrate was concentrated under reduced pressure. The residue was dissolved in dichloromethane (10 ml) and cooled in an ice bath. While stirring vigorously, thereto were added dropwise 4N aqueous sodium hydroxide solution ( 1 ml) and a solution of 2,2,2-trichloroethyl chloroformate (508 mg) in dichloromethane (1 ml) simultaneously.
After stirring further for 30 minutes, the organic layer was collected. After extracting the aqueous layer with chloroform, organic
layers were combined and washed with water and saturated saline. The organic layer was dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography [solvent: hexane-ethyl acetate (2:3)] to obtain 4-[(2S)-2-(tert-butoxycarbonylamino)-3- (methoxy)propionylammo]piperidine- l-carboxylic acid 2,2,2- trichloroethyl ester (840 mg).
MS-APCI(m/z): 476/478[M+H]+
(3) The compound (839 mg) obtained in the above (2) was treated in the same manner as in the above Example 1.001 (2) to obtain 4-[(2S)-2- amino-3-(methoxy)propionylamino]piperidine- l-carboxylic acid 2,2,2- trichloroethyl ester hydrochloride (594 mg). MS-APCI(m/z): 376/378[M+H]+
(4) The compound (250 mg) obtained in the above (3) and 4-benzyl- oxy-3,5-dimethoxybenzoic acid (174 mg) were treated in the same manner as in the above Example 1.001 (3) to obtain 4-[(2S)-2-(4-benzyl- oxy-3,5-dimethoxybenzoylamino)-3-methoxypropionylamino]piperidine- 1-carboxylic acid 2,2,2-trichloroethyl ester (367 mg). MS-APCI(m/z): 646/648[M+H]+ (5) To a solution of the compound (365 mg) obtained in the above (4) in tetrahydrofuran (15 ml) were added acetate buffer (3 ml) and zinc powder (1.5 g), and the mixture was stirred at room temperature for 4.5 hours. Precipitates were removed by filtration, and the filtrate was concentrated under reduced pressure. To the resulted residue were added chloroform and saturated aqueous sodium bicarbonate solution, and the organic layer was collected. The organic layer was washed with saturated saline, and dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure. The residue was purified by NH-silica gel column chromatography [solvent: chloroform- methanol (1:0 to 20: 1)] to obtain 3,5-dimethoxy-N-[(lS)- l-(methoxy-
methyl) -2 -oxo-2- (4-piperidylamino) ethyl] -4- (phenylmethoxy) benzamide (246 mg, the compound of Reference Example 2.011 listed in Table as described hereinafter). Example 3.001 (1) To a solution of L-norvaline methyl ester hydrochloride (1.68 g), 4-hexyloxybenzoic acid (2.22 g) and 1-hydroxybenzotriazole (1.35 g) in chloroform (30 ml) were added l-(3-dimethylaminopropyl)-3-ethyl- carbodiimide hydrochloride (2.87 g) and triethylamine (2.8 ml) in this order, and the mixture was stirred at room temperature for 5 hours. To the reaction mixture was added water (30 ml), and the mixture was vigorously stirred for 10 minutes. The organic layer was collected, and the aqueous layer was further extracted with chloroform. The organic layer were combined, washed with 1 % hydrochloric acid, water, 2 % aqueous potassium carbonate solution and saturated saline, and dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography [solvent: ethyl acetate-hexane (1:5)] to obtain N- [4- (hexyloxy)benzoyl]-L-norvaline methyl ester (3.21 g). MS-APCI(m/z): 336 [M+H]+ (2) - A solution of the compound (3.20 g) obtained in the above (1) in methanol (20 ml) was cooled in an ice bath, and thereto was added 4N aqueous sodium hydroxide solution (6 ml). The mixture was stirred at room temperature for 1.5 hour. The reaction mixture was concentrated under reduced pressure, and the residue was dissolved in water. The mixture was cooled in an ice bath, and thereto was added dropwise a 10 % hydrochloric acid while it was vigorously stirred. The mixture was extracted with chloroform, and the organic layer was washed with water and saturated saline, and dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography
[solvent: methanol-chloroform (1: 10)] to obtain N-[4-(hexyloxy)benzoyl]-
L-norvaline (3.1 g).
MS-ESI(m/z): 320 [M-H]-
(3) To a solution of the compound (64 rag) obtained in the above (2), 2-(l-methylpyrrolidin-2-yl)ethylamine (0.030 ml) and 1-hydroxybenzo- triazole (27 mg) in chloroform (3 ml) were added l-(3-dimethylamino- propyl)-3-ethylcarbodiimide hydrochloride (58 mg) and triethylamine (0.028 ml) in this order, and the mixture was stirred at room temperature for 15 hours. To the reaction mixture was added water (3 ml), and the mixture was vigorously stirred for 10 minutes and extracted with ethyl acetate. The organic layer was washed with water, 1 % aqueous potassium carbonate solution and saturated saline, and dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography [NH] [solvent: methanol-chloroform (1:30)] to obtain 4-(hexyloxy)-N-[(lS)- l-[[[2-(l-methyl-2-pyrrolidinyl)ethyl]amino]- carbonyl] butyl] benzamide (68 mg, the compound of Example 3.001 listed in Table as described hereinafter). Examples 3.002-3.003
The compounds of Examples 3.002-3.003 listed in Table as described hereinafter were obtained in the same manner as in the above Example 3.001. Example 4.001 - 4.003 ,
In the same manner as in the above Example 1.001 using (2S)- 2-(tert-butoxycarbonylamino)-3-methylthiopropionic acid instead of tert-butoxycarbonyl-L-norvaline as a starting compound, the compounds of Example 4.001 - 4.003 listed in Table as described hereinafter were obtained. Example 5.001 - 5.005
In the same manner as in the above Example 1.001 using (2S)- 2-(tert-butoxycarbonylamino)-n-butanoic acid instead of tert-butoxy- carbonyl-L-norvaline as a starting compound, the compounds of
Example 5.001 - 5.005 listed in Table as described hereinafter were obtained.
Reference Example 1.01
(1) To a solution of ethyl vanillate (589 mg) in acetone (15 ml) were added potassium carbonate (828 mg) and 1-bromohexane (0.632 ml) in this order. The mixture was heated under reflux for 24 hours. After the reaction mixture was cooled to room temperature, the precipitates were removed by filtration, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography [solvent: ethyl acetate-hexane (1:5)] to obtain 4- hexyloxy-3-methoxybenzoic acid ethyl ester (840 mg). MS-APCI(m/z): 281 [M+H]+
(2) A solution of the compound (836 mg) obtained in the above (1) in ethanol (15 ml) was cooled in an ice bath, and thereto was added a 4N aqueous sodium hydroxide solution (3 ml) . The mixture was stirred at room temperature for 15 hours. The reaction mixture was concentrated under reduced pressure, and the residue was dissolved in water. The mixture was cooled in an ice bath, and thereto was added dropwise a 10 % hydrochloric acid while the mixture was vigorously stirred. The mixture was extracted with chloroform, and the organic layer was washed with water and saturated saline, and dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography [solvent: methanol-chloroform (1: 15)] to obtain 4-hexyloxy-3- methoxybenzoic acid (666 mg, the compound of Reference Example 1.01 listed in Table as described hereinafter). Reference Examples 1.02-1.07
The compounds of Reference Examples 1.02-1.07 listed in Table as described hereinafter were obtained in the same manner as in the above Reference Example 1.01. Reference Example 1.08
(1) To a solution of 4-hydroxy-3,5-dimethylbenzoic acid (1.66 g) in N,N-dimethylacetamide (20 ml) were added potassium carbonate (5.52 g) and 1-bromohexane (4.2 ml) in this order, and the mixture was vigorously stirred at 1000C for 20 hours. The reaction solution was cooled to room temperature and poured into water, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated saline, and dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography [solvent: ethyl acetate- hexane (1:5)] to obtain 4-hexyloxy-3,5-dimethylbenzoic acid hexyl ester (3.34 g).
MS-APCI (m/z): 335 [M+H]+
(2) To the compound (3.34 g) obtained in the above (1) in methanol (40 ml) was added 4N aqueous sodium hydroxide solution (10 ml). The mixture was stirred at 500C for 24 hours. The reaction solution was cooled to room temperature, and the reaction mixture was concentrated under reduced pressure. The residue was dissolved in water, and the mixture was cooled in an ice bath, and thereto was added dropwise 10 % hydrochloric acid while the mixture was vigorously stirred. The mixture was extracted with chloroform, and the organic layer was washed with water and saturated saline, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography [solvent: methanol-chloroform (1: 10)] to obtain 4-hexyloxy-3,5-dimethylbenzoic acid (2.50 g, the compound of Reference Example 1.08 listed in Table as described hereinafter). Reference Examples 1.09-1.10
The compounds of Reference Examples 1.09-1.10 listed in Table as described hereinafter were obtained by the same manner as in the above Reference Example 1.08. Reference Example 1.11
(1) A solution of 4-phenyl-l-butanol (1.50 g) and pyridine (3.2 ml) in methylene chloride (20 ml) was cooled in an ice bath, and thereto was added dropwise a solution of tosyl chloride (2.86 g) in methylene chloride (10 ml). The mixture was stirred for 2 hours, and washed with water, 10 % hydrochloric acid and saturated saline, and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography [solvent: ethyl acetate-hexane (1:5)] to obtain 4-phenyl- butyl 4-methylbenzenesulfonate (1.60 g). MS-EI (m/z): 304 [M]+
(2) Using the compound obtained in the above (1) and methyl 4- hydroxybenzoate, 4-(4-phenylbutoxy)benzoic acid (the compound of Reference Example 1.11 listed in Table as described hereinafter) was obtained in the same manner as in the above Reference Example 1.01. Reference Example 1.12 - 1.23
In the same manner as in the above Reference Example 1.01, the compounds of Examples 1.12 - 1.23 listed in Table as described hereinafter were obtained.
Reference Example 1.24 - 1.27 In the same manner as in the above Reference Example 1.08, the compounds of Examples 1.24 - 1.27 listed in Table as described hereinafter were obtained.
Reference Example 1.28
(1) To a solution of 4-fluorobenzoic acid methyl ester (500 μl) in dimethylacetamide (5ml) were added n-hexylamine (635 μl) and potassium carbonate (0.8g) in this order. The mixture was stirred at
800C for 20 hours. The reaction mixture was cooled to room temperature, and thereto was added water. The reaction mixture was extracted with ethyl acetate. The organic layer was washed with saturated saline, and dried over anhydrous sodium sulfate. The solvent was evaporated under reduced
pressure, and the residue was purified by silica gel column chromatography [solvent: hexane-ethyl acetate (99: 1 to 9: 1)] to obtain 4-
(hexylamino) benzoic acid methyl ester (439 mg).
MS-APCI(m/z): 236[M+H]+ (2) To a solution of the compound (400 mg) obtained in the above (1) in methanol (12 ml) were added a 4N aqueous sodium hydroxide solution (2. 1 ml), and the mixture was stirred for 24 hours at 50°C.
The reaction mixture was cooled to room temperature, and methanol was evaporated under reduced pressure. To an aqueous solution of the residue, while cooling in an ice bath, was added 6N hydrochloride
(1.4 ml) to neutralize. Then the mixture was extracted with ethyl acetate.
The organic layer was washed with saturated saline, and dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography [solvent: hexane-ethyl acetate (9: 1 to 3: 1)] to obtain 4-
(hexylamino)benzoic acid (312 mg, the compound of Reference Example
1.28 listed in Table as described hereinafter).
Reference Example 1.29 - 1.30 In the same manner as in the above Reference Example 1.28, the compounds of Examples 1.29 - 1.30 listed in Table as described hereinafter were obtained.
Reference Example 1.31
(1) Ethyl 3,4-dihydroxybenzoate was treated in the same manner as in the above Reference Example 1.01 (1) to obtain ethyl 4-hexyloxy-3- hydroxybenzoate .
(2) A solution of the compound (100 mg) obtained in the above (1) in chloroform (5 ml) was cooled in an ice bath, and thereto were added chloromethyl methyl ether (43 μl) and diisopropylethylamine (96 μl) in this order. The mixture was stirred at room temperature for 3 days.
The reaction mixture was washed with water, saturated aqueous sodium bicarbonate solution and saturated saline, and thereafter, dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography [solvent: hexane-ethyl acetate (99: 1 to 92:8)] to obtain 4-hexyloxy-3-(methoxymethoxy)benzoic acid ethyl ester (115 mg).
MS-APCI(m/z): 328[M+NH4]+
(3) The compound (100 mg) obtained in the above (2) was treated in the same manner as in the above Reference Example 1.01 (2) to obtain 4-hexyloxy-3-(methoxymethoxy) benzoic acid (the compound of
Reference Example 1.31 listed in Table as described hereinafter). Reference Example 1.32
(1) To a solution of vanillic acid ethyl ester (500 mg) in trifluoroacetic acid (5 ml) was added hexamethylenetetramine (179 mg). The mixture was heated under reflux for 19 hours. The reaction mixture was cooled to room temperature, and concentrated under reduced pressure.
The residue was dissolved in ethyl acetate, washed with water and saturated saline, dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography [solvent: hexane-ethyl acetate(9: l to 4: 1)] to obtain 3-formyl-4-hydroxy-5-methoxybenzoic acid ethyl ester (177 mg).
MS-ESI(m/z): 223[M-Hf (2) To a solution of the compound (150 mg) obtained in the above (1) in methanol (15 ml) were added hydrochloric acid (one drop) and 10 % palladium on activated carbon (75 mg). The mixture was stirred vigorously for 1 hour under hydrogen atmosphere. After removing the catalyst from the reaction mixture by filtration, the filtrate was concentrated under reduced pressure. The residue was purified by
silica gel column chromatography [solvent: hexane-ethyl acetate(99: 1 to 95:5)] to obtain 4-hydroxy-3-methoxy-5-methylbenzoic acid ethyl ester (129 mg).
MS-APCI(m/z): 211[M+H]+ (3) The compound (100 mg) obtained in the above (2) was treated in the same manner as in the above Reference Example 1.01 to obtain 4- hexyloxy-3-methoxy-5-methylbenzoic acid (the compound of Reference Example 1.32 listed in Table as described hereinafter). Reference Example 1.33 In the same manner as in the above Reference Example 1.31, the compound of Example 1.33 listed in Table as described hereinafter was obtained. Reference Example 1.34
(1) 4-Hydroxy-3-nitrobenzoic acid methyl ester was treated in the same manner as in the above Reference Example 1.01 (1) to obtain 4- hexyloxy-3-nitrobenzoic acid methyl ester.
(2) To a solution of the compound (615 mg) obtained in the above (1) in methanol (15 ml) was added 10 % palladium on activated carbon (150. mg). The mixture was stirred vigorously for 2 hours under hydrogen atmosphere. After removing the catalyst from the reaction mixture by filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography [solvent: hexane-ethyl acetate(5: l)] to obtain 3-amino- 4-hexyloxybenzoic acid ethyl ester (445 mg) . MS-APCI(m/z): 252[M+H]+
(3) To a solution of the compound (100 mg) obtained in the above (2) in chloroform (3 ml) were added l-(3-dimethylaminopropyl)-3-ethyl- carbodiimide hydrochloride (159 mg) and formic acid (30 μl). The mixture was stirred at room temperature for 3.5 hours. The reaction mixture was washed with water and saturated saline, and dried over
anhydrous sodium sulfate, followed by removing the solvent under reduced pressure. The residue was purified by silica gel column chromatography [solvent: hexane-ethyl acetate (9: 1 to 4: 1)] to obtain 3- (formylamino)-4-hexyloxybenzoic acid methyl ester (104 mg). MS-APCI(m/z): 297[M+NH4]+
(4) The compound obtained in the above (3) was treated in the same manner as in the above Reference Example 1.01 (2) to obtain 3-(formyl- amino)-4-hexyloxybenzoic acid (the compound of Reference Example 1.34 listed in Table as described hereinafter). Reference Example 1.35
(1) A mixture of 6-bromo-2-naphthalenecarboxylic acid methyl ester (3.0 g), phenylboronic acid (2.07 g), dichlorobis(triphenylphosphine) palladium (II) (793 mg), 2M aqueous sodium carbonate solution (12 ml) and dimethoxyethane (48 ml) was stirred at 800C under argon atmosphere for 3.5 hours. The reaction solution was cooled to room temperature, and thereto was added ethyl acetate, and the mixture was stirred vigorously for about 10 hours.
The resulting precipitate was removed by filtration. The filtrate was diluted with ethyl acetate, and washed with water and saturated saline. The organic layer was dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography [solvent: chloroform- hexane (2: 1)] to obtain 6-phenyl-2-naphthalenecarboxylic acid methyl ester. MS-APCI(m/z): 263[M+H]+
(2) To a suspension of the compound (410 mg) obtained in the above (1) in methanol-tetrahydrofuran (1: 1, 20 ml) was added 4N aqueous sodium hydroxide solution (1.56 ml), and the mixture was stirred at 80°C for 12 hours. The reaction solution was cooled to room temperature, and diluted with water, and washed with diethyl ether.
To the obtained aqueous phase was added dropwise 10 % hydrochloric acid, and the mixture was extracted with ethyl acetate. The extract was washed with saturated saline, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The resulting powdery residue was washed with isopropyl ether, and dried under reduced pressure to obtain 6-phenyl-2-naphthalenecarboxylic acid (158 mg, the compound of Reference Example 1.35 listed in Table as disclosed hereinafter) . Reference Example 1.36 - 1.38 In the same manner as in the above Reference Example 1.35, the compounds of Examples 1.36 - 1.38 listed in Table as described hereinafter were obtained. Reference Example 1.39
(1) A suspension of 6-hydroxy-2-naphthalenecarboxylic acid methyl ester (7.0 g) in acetic acid (100 ml) was cooled in an ice bath, and thereto was added dropwise a concentrated nitric acid (52.5 ml). The mixture was stirred for 30 minutes while cooling in an ice bath. The reaction mixture was poured into ice water, and then extracted with ethyl acetate. The organic layer was washed with water and saturated saline, and dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography [solvent: hexane-ethyl acetate (3: 1)] to obtain 6-hydroxy-5-nitro-2-naphthalenecarboxylic acid methyl ester (5.1 g) MS-ESI (m/z): 246 [M-H]-
(2) A solution of the compound (2.93 g) obtained in the above (1) in chloroform ( 100 ml) was cooled in an ice bath, and thereto were added pyridine (3.83 ml) and anhydrous trifluoromethanesulfonic acid (3.99 ml) in this order. The mixture was stirred at room temperature for 19 hours. The reaction mixture was washed with water, 5 % hydrochloric
acid and saturated saline, and was dried over anhydrous sodium sulfate.
The solvent was evaporated under reduced pressure. To the residue were added chloroform and hexane, and the mixture was stirred. The precipitate was collected by filtration to obtain 5-nitro-6-(trifluoro- methanesulfonyloxy)-2-naphthalenecarboxylic acid methyl ester (3.51 g). MS-APCI(m/ z): 397[M+NH4]+
(3) To a solution of the compound (260 mg) obtained in the above (2) in dimethoxyethane (6 ml) were added phenylboric acid (125 mg) tetrakis(triphenylphosphine)palladium (80 mg) and 2M aqueous sodium carbonate solution in this order. The mixture was stirred at 800C for 3 hours. The reaction mixture was cooled to room temperature, and thereto were added ethyl acetate and water, and the mixture was stirred for 1 hour. The organic layer was collected, washed with water and saturated saline, and dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography [solvent: hexane-ethyl acetate (4: 1)] to obtain 5-nitro-6-phenyl-2-naphthalenecarboxylic acid methyl ester (175 mg). MS-APCI(Hi/ z): 308[M+H]+
(4) The compound obtained in the above (3) was treated in the same manner as in the above Reference Example 1.01 (2) to obtain 5-nitro~6- phenyl-2-naphthalenecarboxylic acid (the compound of Reference Example 1.39 listed in Table as described hereinafter). Reference Example 1.40
(1) To a solution of 5-nitro-6-(trifluoromethanesulfonyloxy)-'2- naphthalenecarboxylic acid (100 mg) in acetonitrile (5 ml) was added piperidine (80 μl). The mixture was heated under reflux for 2.5 hours. The reaction mixture was cooled to room temperature, and then concentrated under reduced pressure. The residue was purified by
silica gel column chromatography [solvent: hexane-ethyl acetate (9: 1)] to obtain 5-nitro-6-piperidino-2-naphthalenecarboxylic acid methyl ester (83 mg).
MS-APCI (m/z): 315 [M+H]+ (2) The compound (80 mg) obtained in the above (1) was dissolved in methanol-tetrahydrofuran (1: 1) (6 ml), and thereto was added 4N aqueous sodium hydroxide solution (0.32 ml). The mixture was stirred at room temperature for 19 hours. The reaction mixture was concentrated under reduced pressure. The residue was dissolved in water, and thereto was added dropwise 6N hydrochloric acid while cooling in an ice bath. After stirring at room temperature for 1 hour, the precipitate was collected by filtration and dried under reduced pressure to obtain 5-nitro-6-piperidino-2-naphthalenecarboxylic acid (58 mg, the compound of Reference Example 1.40 listed in Table as described hereinafter). Reference Example 1.41
(1) To a solution of 6-hydroxy-2-naphthalenecarboxylic acid methyl ester (202 mg) in chloroform (10 ml) were added copper(II) acetate (218 mg), Molecular sieves 4A (200 mg), 4-fluorophenylboronic acid (280 mg) and triethylamine (0.697 ml) in this order. The mixture was stirred at room temperature for 22 hours. To the reaction mixture was added a saturated aqueous sodium bicarbonate solution, and the mixture was stirred at room temperature for 30 minutes. The organic layer was collected. The aqueous layer was further extracted with chloroform. The organic layers were combined, washed with saturated saline, and dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography [solvent: hexane-ethyl acetate (9: 1)] to obtain 6-(4- fluorophenyloxy)-2-naphthalenecarboxylic acid methyl ester (119 mg). MS-APCI(m/z): 297[M+H]+
(2) The compound obtained in the above (1) was treated in the same manner as in the above Reference Example 1.40 (2) to obtain 6-(4- fluorophenyloxy)-2-naphthalenecarboxylic acid (the compound of Reference Example 1.41 listed in Table as described hereinafter). Reference Example 2.01
(1) The mixture of dimethylamine hydrochloride (8.16 g) and acetone (5.81 g) was cooled in an ice bath, and thereto was added dropwise a solution of potassium cyanide (6.52 g) in water (50 ml). The mixture was stirred at room temperature for 22 hours. The reaction mixture was extracted with ethyl acetate. The organic layer was washed with saturated saline, and dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure to obtain 2- (dimetylamino) -2 -methylpropionitrile .
(2) A suspension of lithium aluminum hydride (10.36 g) in tetrahydrofuran (150 ml) was cooled in an ice bath under argon atmosphere, and thereto was added dropwise a solution of sulfuric acid (13.4 g) in tetrahydrofuran (30 ml). After the mixture was stirred for 1 hour, thereto was added dropwise a solution of the compound obtained in the above (1) in tetrahydrofuran (30 ml). The reaction mixture was taken of from the ice bath and stirred for 1.5 hours. Then, the reaction mixture was cooled again in an ice bath, and thereto were added dropwise water (10.4 ml) and 4N aqueous sodium hydroxide solution (31.2 ml) in this order.
The reaction mixture was taken off from ice bath and stirred for 12 hours. Precipitates were removed by filtration, and the filtrate was concentrated under reduced pressure. The residue was dissolved in dioxane (10 ml), and thereto was added 4N solution of hydrogen chloride in dioxane, and the mixture was stirred at room temperature for 30 minutes. The reaction mixture was concentrated under reduced pressure. To the residue was added ethanol (100 ml), and the
mixture was stirred at room temperature for 30 minutes. The precipitate was collected by filtration and dried under reduced pressure to obtain 2-dimethylamino-2-methylpropylamine (9.7 g, the compound of Reference Example 2.01 listed in Table as described hereinafter). Reference Example 2.02 - 2.04
In the same manner as in the above Reference Example 2.01, the compounds of Examples 2.02 - 2.04 listed in Table as described hereinafter were obtained. Reference Example 2.05 (1) A suspension of sodium hydride (2.96 g) in diethyl ether was cooled in an ice bath, and thereto was added dropwise a solution of diethyl cyanomethylphosphonate (13.4 g) in diethyl ether (30 ml). Then, thereto was added dropwise a solution of cyclopentanone (5.65 g) in diethyl ether (10 ml), and the mixture was stirred for 10 minutes while cooling. The reaction mixture was warmed to room temperature, and then stirred for 12 hours. To the reaction mixture was added water, and after stirred for a while, the mixture was extracted with diethyl ether. The organic layer was washed with saturated saline, and dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure to obtain cyclopentylideneacetonitrile.
(2) To the compound obtained in the above (1) (1 g) was added 30% methylamine-methanol solution (11 ml). The mixture was heated in a bath of temperature 600C and stirred for 19 hours in a sealed tube. The reaction mixture was cooled to room temperature, and concentrated under reduced pressure. To the residue were added ethyl acetate and 5% hydrochloride, and aqueous layer was collected". The aqueous layer was cooled in an ice bath, and thereto was added potassium carbonate. The aqueous layer was concentrated under reduced pressure, and to the residue was added methanol. Precipitates were removed by filtration. The filtrate was concentrated
under reduced pressure, and the residue was purified by silica gel column chromatography [NH] [solvent: chloroform] to obtain (l-(methyl- amino)cyclopentyl)acetonitrile (479 mg).
MS-APCI(m/z): 139[M+H]+ (3) To a solution of the compound (479 mg) obtained in the above (2) in dichloromethane (20 ml) were added 37% aqueous formalin solution (0.5 ml), sodium cyanoborohydride (240 mg) and acetic acid (0.6 ml) in this order. The mixture was stirred at room temperature for 4 hours. To the reaction mixture was added aqueous solution of potassium carbonate, and after stirred for a while, the mixture was extracted with 10% methanol-chloroform. The organic layer was washed with saturated saline, and dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography [solvent: chloroform- methanol (10: 1)] to obtain ( 1 - (dimethylamino) cyclopentyl) acetonitrile (458 mg).
MS-APCI(m/z): 153 [M+H]+
(4) The compound obtained in the above (3) was treated in the same manner as in the above Reference Example 2.01 (1) to obtain [l-(2- aminoethyl) cyclopentyl] dimethylamine dihydrochloride (the compound of Reference Example 2.05 listed in Table as described hereinafter).
Table A
Table B
Table C
Table D
Table E
Table of Reference Examples
Claims
1. A norvaline derivative of the formula [I]:
X is -CH2- , -O- , -S- or a single bond ;
Ar is an optionally substituted aryl or an optionally substituted lower cycloalkyl; n is an integer of 0 to 2; R1 and R2 are the following (i), (ii) or (iii):
(i) each is independently a hydrogen atom or a lower alkyl;
(ii) R1 and R2 are combined together to form a lower alkylene; or
(iii) R1 is a hydrogen atom or a lower alkyl and R2 is combined
together with R4 or R6 to form a lower alkylene, when R is R3 and R4 are the following (i), (ii) or (iii):
(i) each is independently a hydrogen atom or a lower alkyl;
(ii) R3 and R4 are combined together to form a lower alkylene; or
(iii) R3 is a hydrogen atom or a lower alkyl and R4 is combined
together with R2 or R6 to form a lower alkylene, when R is R6 ;
R5 and R6 are the following (i), (ii) or (iii):
(i) each is independently a lower alkyl optionally substituted with hydroxyl group(s), or a hydrogen atom;
(ii) R5 and R6 are combined together with the adjacent nitrogen atom to form an optionally substituted nitrogen-containing aliphatic 5- to 6- membered heterocyclic group;
(iii) R5 is a lower alkyl optionally substituted with hydroxyl group(s), or a hydrogen atom, and R6 is combined together with R2 or R4 to form a lower alkylene;
R7 is a lower alkyl; provided that when R5 and R6 are combined together with the adjacent nitrogen atom to form a morpholine ring, then Ar has at least one substituent other than halogen atom, methoxy or phenyl; and when R is -OR7 and X is a single bond, then Ar is an optionally substituted phenyl, an optionally substituted naphthyl or an optionally substituted lower cycloalkyl], or a pharmaceutically acceptable salt thereof.
2. The compound according to Claim 1, which has a chemical structure of the formula [Ia]:
3. The compound according to Claim 1 or 2, wherein X is -CH2-.
4. The compound according to Claim 1 or 2, wherein X is -O- .
5. The compound according to Claim 1 or 2, wherein X is -S-.
6. The compound according to Claim 1 or 2, wherein X is a single bond.
7. The compound according to any one of Claims 1 to 6 wherein Ar is a group selected from an optionally substituted phenyl and an optionally substituted naphthyl.
8. The compound according to any one of Claims 1 to 7,
9. The compound according to Claims 8, wherein a nitrogen-containing aliphatic 5- to 6- membered heterocyclic group portion of an "optionally substituted nitrogen-containing aliphatic 5- to 6- membered heterocyclic group" formed by R5 and R6 together with the adjacent nitrogen is 1-pyrrolidinyl, 1-piperidyl or 1-piperazinyl.
10. The compound according to any one of Claims 1 to 9, wherein the substituent(s) of the optionally substituted aryl or the optionally substituted lower cycloalkyl represented by Ar is group(s) selected from the following: halogen atom; nitro group; cyano group; hydroxyl group; amino group optionally substituted with 1 or 2 substituent(s) selected from lower alkyl and formyl; C1-7 alkyl; lower alkoxy optionally substituted with phenyl optionally substituted with group(s) selected from halogen atom, lower alkyl and halo(lower)alkyl; lower cycloalkoxy; lower alkylthio; phenyl optionally substituted with group(s) selected from halogen atom, lower alkyl and lower alkoxy; 1-piperidyl optionally substituted with group (s) selected from lower alkyl and phenyl; phenoxy optionally substituted with halogen atom(s) .
11. - The compound according to any one of Claims 1 to 10, wherein the substituent(s) of the "optionally substituted nitrogen-containing aliphatic 5- to 6- membered heterocyclic group" formed by R5 and R6 together with the adjacent nitrogen is lower alkyl.
12. A free form of each compound as disclosed in Examples, or a pharmaceutically acceptable salt thereof.
13. A method for inhibition of GlyT2 or for treatment or prophylaxis of a disease or condition, which comprises administering to a patient an effective dose of the compound according to any one of Claims 1 to 12.
14. The method according to Claim 13, wherein the disease or condition is a disease or condition which can be expected to be improved by inhibition of GlyT2.
15. The method according to Claim 13, wherein the disease or condition is pain, muscle spasticity, tinnitus, epilepsy, or urological disorder.
16. The method according to Claim 13, wherein the disease or condition is inflammatory pain or neuropathic pain.
17. Use of the compound according to any one of Claims 1 to 12 for manufacture of a medicament.
18. The use according to Claim 17, wherein the medicament is for inhibition of GlyT2 or for treatment or prophylaxis of a disease or condition which can be expected to be improved by inhibition of GlyT2.
19. The use according to Claim 17, wherein the medicament is for treatment or prophylaxis of pain, muscle spasticity, tinnitus, epilepsy, or urological disorder.
20. The use according to Claim 17, wherein the medicament is for treatment or prophylaxis of inflammatory pain or neuropathic pain.
21. A pharmaceutical composition comprising the compound according to any one of Claims 1 to 12 as an effective ingredient.
22. The pharmaceutical composition according to Claim 21, wherein the pharmaceutical composition is for inhibition of GlyT2 or for treatment or prophylaxis of a disease or condition which can be expected to be improved by inhibition of GlyT2.
23. The pharmaceutical composition according to Claim 21, wherein the pharmaceutical composition is for treatment or prophylaxis of pain, muscle spasticity, tinnitus, epilepsy, or urological disorder.
24. The pharmaceutical composition according to Claim 21, wherein the pharmaceutical composition is for treatment or prophylaxis of inflammatory pain or neuropathic pain.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/795,966 US7718703B2 (en) | 2005-01-25 | 2006-01-24 | Norvaline derivative and method for preparation thereof |
JP2007534937A JP4847459B2 (en) | 2005-01-25 | 2006-01-24 | Norvaline derivative and method for producing the same |
EP06712540A EP1846366B1 (en) | 2005-01-25 | 2006-01-24 | Norvaline derivative and method for preparation thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64650205P | 2005-01-25 | 2005-01-25 | |
US60/646,502 | 2005-01-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006080477A1 true WO2006080477A1 (en) | 2006-08-03 |
Family
ID=36353346
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/301394 WO2006080477A1 (en) | 2005-01-25 | 2006-01-24 | Norvaline derivative and method for preparation thereof |
Country Status (5)
Country | Link |
---|---|
US (1) | US7718703B2 (en) |
EP (1) | EP1846366B1 (en) |
JP (1) | JP4847459B2 (en) |
TW (1) | TWI406839B (en) |
WO (1) | WO2006080477A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008022938A1 (en) * | 2006-08-21 | 2008-02-28 | F. Hoffmann-La Roche Ag | Di-aromatic substituted amides as inhibitors for glyt1 |
WO2008025694A1 (en) * | 2006-08-30 | 2008-03-06 | F. Hoffmann-La Roche Ag | Inhibitors for glyt-1 |
EP2461683A1 (en) * | 2009-08-05 | 2012-06-13 | Biogen Idec MA Inc. | Bicyclic aryl sphingosine 1-phosphate analogs |
US9340527B2 (en) | 2011-02-07 | 2016-05-17 | Biogen Ma Inc. | S1P modulating agents |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5165950B2 (en) * | 2006-07-21 | 2013-03-21 | 田辺三菱製薬株式会社 | Pharmaceutical composition |
EP3263568B1 (en) | 2011-07-18 | 2021-08-25 | Merck Patent GmbH | Benzamides |
PE20160759A1 (en) * | 2015-06-09 | 2016-07-28 | Gonzalez Sierra Andres Fernando | IMPROVED DOSING SYSTEM |
WO2020097389A1 (en) | 2018-11-09 | 2020-05-14 | Vivace Therapeutics, Inc. | Bicyclic compounds |
AU2020257207A1 (en) * | 2019-04-16 | 2021-11-25 | Vivace Therapeutics, Inc. | Bicyclic compounds |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63301868A (en) * | 1987-06-01 | 1988-12-08 | Nippon Kayaku Co Ltd | N-(2-chloroisonicotinoyl)amino acid derivative and agricultural and horticultural fungicide comprising said derivative as active ingredient |
WO2003010132A1 (en) * | 2001-07-17 | 2003-02-06 | Akzo Nobel N.V. | N-[(1-dimethylaminocycloalkyl)methyl]benzamide derivatives |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007503440A (en) | 2003-08-27 | 2007-02-22 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Aryl piperidine amide |
WO2005044810A1 (en) | 2003-10-30 | 2005-05-19 | Janssen Pharmaceutica, N.V. | Glyt2 modulators |
-
2006
- 2006-01-24 JP JP2007534937A patent/JP4847459B2/en not_active Expired - Fee Related
- 2006-01-24 WO PCT/JP2006/301394 patent/WO2006080477A1/en active Application Filing
- 2006-01-24 US US11/795,966 patent/US7718703B2/en not_active Expired - Fee Related
- 2006-01-24 EP EP06712540A patent/EP1846366B1/en not_active Not-in-force
- 2006-01-25 TW TW095102778A patent/TWI406839B/en not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63301868A (en) * | 1987-06-01 | 1988-12-08 | Nippon Kayaku Co Ltd | N-(2-chloroisonicotinoyl)amino acid derivative and agricultural and horticultural fungicide comprising said derivative as active ingredient |
WO2003010132A1 (en) * | 2001-07-17 | 2003-02-06 | Akzo Nobel N.V. | N-[(1-dimethylaminocycloalkyl)methyl]benzamide derivatives |
Non-Patent Citations (2)
Title |
---|
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; YOSHIDA, HIROSHI ET AL: "Preparation of N-(2-chloroisonicotinoyl) amino acid amides as agrochemical microbicides", XP002382218, retrieved from STN Database accession no. 1989:213341 * |
WOLIN, RONALD L. ET AL: "Novel glycine transporter type-2 reuptake inhibitors. Part 1: .alpha.-amino acid derivatives", BIOORGANIC & MEDICINAL CHEMISTRY, 12(16), 4477 4492 CODEN: BMECEP; ISSN: 0968-0896, 2004, XP002382216 * |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7964645B2 (en) | 2006-08-21 | 2011-06-21 | Hoffmann-La Roche Inc. | Di-aromatic substituted amides as inhibitors for GlyT-1 |
WO2008022938A1 (en) * | 2006-08-21 | 2008-02-28 | F. Hoffmann-La Roche Ag | Di-aromatic substituted amides as inhibitors for glyt1 |
WO2008025694A1 (en) * | 2006-08-30 | 2008-03-06 | F. Hoffmann-La Roche Ag | Inhibitors for glyt-1 |
US7589089B2 (en) | 2006-08-30 | 2009-09-15 | Hoffmann-La Roche Inc. | Inhibitors for GlyT-1 |
US9827258B2 (en) | 2009-08-05 | 2017-11-28 | Biogen Ma Inc. | Bicyclic aryl sphingosine 1-phosphate analogs |
EP2461683A1 (en) * | 2009-08-05 | 2012-06-13 | Biogen Idec MA Inc. | Bicyclic aryl sphingosine 1-phosphate analogs |
EP2461683A4 (en) * | 2009-08-05 | 2013-02-20 | Biogen Idec Inc | Bicyclic aryl sphingosine 1-phosphate analogs |
US8802659B2 (en) | 2009-08-05 | 2014-08-12 | Biogen Idec Ma Inc. | Bicyclic aryl sphingosine 1-phosphate analogs |
US9186367B2 (en) | 2009-08-05 | 2015-11-17 | Boigen Ma Inc. | Bicyclic aryl sphingosine 1-phosphate analogs |
US9572824B2 (en) | 2009-08-05 | 2017-02-21 | Biogen Ma Inc. | Bicyclic aryl sphingosine 1-phosphate analogs |
US10166250B2 (en) | 2009-08-05 | 2019-01-01 | Biogen Ma Inc. | Bicyclic aryl sphingosine 1-phosphate analogs |
US9340527B2 (en) | 2011-02-07 | 2016-05-17 | Biogen Ma Inc. | S1P modulating agents |
US10034869B2 (en) | 2011-02-07 | 2018-07-31 | Biogen Ma Inc. | S1P modulating agents |
US9808449B2 (en) | 2011-02-07 | 2017-11-07 | Biogen Ma Inc. | S1P modulating agents |
US10406144B2 (en) | 2011-02-07 | 2019-09-10 | Biogen Ma Inc. | SIP modulating agents |
US10894040B2 (en) | 2011-02-07 | 2021-01-19 | Biogen Ma Inc. | S1P modulating agents |
Also Published As
Publication number | Publication date |
---|---|
EP1846366A1 (en) | 2007-10-24 |
TW200637807A (en) | 2006-11-01 |
JP4847459B2 (en) | 2011-12-28 |
US20080076769A1 (en) | 2008-03-27 |
JP2008528439A (en) | 2008-07-31 |
TWI406839B (en) | 2013-09-01 |
EP1846366B1 (en) | 2011-08-03 |
US7718703B2 (en) | 2010-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1846366B1 (en) | Norvaline derivative and method for preparation thereof | |
JP6799596B2 (en) | Oxime compounds as agonists of muscarinic M1 and / or M4 receptors | |
US7199134B2 (en) | Hydroxamic acid compounds and methods of use thereof | |
KR101866858B1 (en) | Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use | |
CA2974477C (en) | Therapeutic isoxazole compounds | |
EP1286967B1 (en) | Cyclohexane derivatives and their use as therapeutic agents | |
US11753370B2 (en) | Methods of making deuterium-enriched N-acetylcysteine amide (d-NACA) and (2R, 2R′)-3,3′-disulfanediyl bis(2-acetamidopropanamide) (diNACA) and using d-NACA and diNACA to treat diseases involving oxidative stress | |
US20060063792A1 (en) | Substituted morphinans and methods of their use | |
US7381721B2 (en) | Substituted piperidine compounds | |
HUT74103A (en) | Aroyl-piperidine derivative | |
TW201213329A (en) | Pyrazine derivatives as ENaC blockers | |
JPH11505237A (en) | Diaryldiamine derivatives and their use as delta opioid (ant) -agonists | |
EP1166781A1 (en) | Proteasome inhibitors | |
US20170022250A1 (en) | Tripeptide epoxyketone compound constructed by heterocycle and preparation method and use thereof | |
JP2011516399A (en) | Novel peptide deformylase-inhibiting compound and method for producing the same | |
KR20060004907A (en) | Saturated quinoxaline derivatives and their use as metabotropic glutamate receptor ligands | |
JP5165950B2 (en) | Pharmaceutical composition | |
EP3628664A1 (en) | Irreversible inhibitors of kras g12c mutant | |
JP2004522716A (en) | Substituted cyclohexane derivatives and their use in medicaments for treating cardiovascular diseases | |
US10590101B2 (en) | Benzo-N-hydroxy amide compounds having antitumor activity | |
US9636346B2 (en) | Alpha-oxoacyl amino-caprolactam derivative | |
SK43099A3 (en) | Hydroxamic acid derivatives, process for their preparation and their use | |
WO2023091565A1 (en) | Nsd2-targeted chemical degraders and compositions and methods of use thereof | |
US20210380538A1 (en) | Novel imidazole compounds, process for the synthesis and uses thereof | |
JP2013249257A (en) | Glycine transporter inhibitory substance |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007534937 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11795966 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006712540 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2006712540 Country of ref document: EP |